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Abstract   
Introduction: Several epidemiological studies have suggested that the regular moderate 
consumption of red wine confers cardioprotection. However, the exact components in red wine 
that confer this effect are unclear. Previous studies performed in our laboratory suggest that 
neither the well-known polyphenol resveratrol nor alcohol (12%) present in red wine contribute 
to the cardioprotective effect of red wine when administered chronically, on their own. 
Therefore, other compounds present in red wine may contribute to its beneficial effects.  
Aims: The aim of the study was to explore whether melatonin, recently discovered in red wine, 
may play a vital role in red wine-induced cardioprotection. Furthermore, we propose that the 
protective effect may be mediated via the activation of the survivor-acting factor enhancement 
(SAFE) pathway that involves two integral components, tumour necrosis factor α and signal 
transducer and activator of transcription 3 (STAT3).  
Methods: The drinking water of either male Wistar rats, TNF KO or STAT3 KO mice and their 
wild-type littermates were supplemented with a French Cabernet Sauvignon (12%  alcohol by 
volume) or melatonin (75ng/ℓ) to a final concentration corresponding to the concentration 
found in two glasses of wine per day. After 14 days of treatment hearts were subjected to an 
ex vivo or an in vivo ischemia reperfusion insult or to a permanent ligation of the left 
descending coronary artery as a model of ischemic heart failure. Functional parameters and 
infarct size were assessed.   
Main Findings: The chronic moderate consumption of red wine for 14 days reduced infarct 
size from 60±2.3% to 23.3±1.8% after ischemia reperfusion injury, p<0.001. The pretreatment 
with melatonin protected to a similar extent as red wine given on its own (infarct size of 
20.1±1.7%, p<0.001). Interestingly, the cardioprotective effect of red wine was partially 
abolished with prazosin, a melatonin receptor 3 inhibitor (40±0.9%, p<0.001 vs. wine). 
Furthermore, the cardioprotective effects of regular moderate consumption of red wine or 
melatonin were abolished in STAT3 KO and TNF KO mice.    
In a model of ischemic heart failure melatonin improved ejection fraction and fractional 
shortening compared to plain drinking water control in wild-type mice (p<0.001).  The 
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protective effect of melatonin was not abolished in TNK KO and STAT3 KO mice (p<0.001 vs. 
control), therefore suggesting that the long-term treatment with melatonin in ischemic heart 
failure protects independently of the SAFE pathway.  
Conclusion: Our novel findings suggest that the moderate regular consumption of red wine 
(equivalent to 2-3 glasses per day) confers cardioprotection, in part due to its melatonin 
content. The protective effect against ischemia I/R injury of both melatonin and red wine is 
mediated via the activation of melatonin receptor 3 and the activation of the SAFE pathway 
while the protective effect of melatonin against ischemic heart failure is independent of the 
SAFE pathway. Melatonin is a safe, cheap and easily accessible drug that may be considered 
as an innovative therapeutic agent in the treatment against acute myocardial infarction and 
ischemic heart failure.   
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1 Prevalence of cardiovascular disease (CVD) worldwide 
CVD is a broad term that describes diseases affecting the heart and its circulatory 
system.These include pathologies, such as hypertrophy, atrophy, ischemia, 
hypertension, stroke and inflammatory disease. It is estimated that by 2020, CVD will 
become the leading cause of death worldwide, and at present it accounts for more than 
73% of global mortality (Murray et al., 1996). Over 80% of all CVD deaths occur in low- 
to middle-income populations (Bradshaw et al., 2005) (see Figure 1).  
 
Figure 1: Cardiovascular disease is a growing burden in low- to middle- income countries (WHO 2009). 
 
The cost of managing CVD is staggering, especially in the United States with an 
estimated cost of $300 billion annually, which is equal to the entire gross domestic 
product (GDP) of the African continent (Mensah et al., 2008). CVD affects both 
developed and developing countries (Steyn et al., 2005a). Developing countries face a 
double burden, with a high rate of infectious diseases and an increase in chronic 
diseases of lifestyle, frequently associated with socioeconomic imbalances.  
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Furthermore, it is predicted that ischemic heart disease (IHD) will be the leading cause 
of death in Africa by the year 2030 (Mensah et al., 2008). Sub-Saharan Africa is in the 
first stage of epidemiological transition, with the CVD rate escalating to almost half the 
rate of CVD in developed countries. Even though human immunodeficiency virus (HIV) 
is the leading cause of death in this region, CVD is the second overall killer and the first 
among those of over 30 years of age. There is a profound increase in CVD in urban 
rather that rural dwellers and the demographic trends also demonstrate a gradual 
increased risk with age (Sliwa et al., 2008).  
In South Africa, IHD is highest among whites, Asians and coloureds, with low mortality 
rates found in blacks (Steyn et al., 2005b). However, 88% of new heart failure patients 
in South Africa are blacks with untreated high blood pressure (Steyn et al., 2005; 
Stewart et al., 2006). In the Western Cape Province (the region around Cape Town), 
CVD is already the number one killer (Bradshaw et al., 2003). The upward trend of CVD 
is a result of increased risk factors (see Figure 2). 
 
Figure 2: Epidemiological transition in the Western Cape. Non-communicable diseases are on the incline 
(Mayosi et al., 2009).  
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1.1 Ischemic heart disease (IHD) 
IHD is characterised by the reduced blood flow to the heart. It is an imbalance between 
supply and demand of oxygen. The coronary artery supplies the heart cells with blood, 
which contains the necessary nutrients and oxygen for the heart; a partial or complete 
obstruction in this artery will reduce the blood flow (Opie et al., 2004). An obstruction 
may develop from atherosclerotic plaque deposition, which partially or wholly blocks a 
coronary artery. 
Atherosclerotic plaque results from an accumulation of oxidised lipoproteins taken up by 
the macrophage, which develops into yellow fatty streaks on the endothelium. 
Thereafter, a thin fibrous cap forms and eventually ruptures, subsequently increasing 
the release of thromboxane-A3 and serotonin, which in turn, promote platelet 
aggregation, vasoconstriction and clot formation (thrombus) (Bronte-Stewart et al., 
1988). The formation of a thrombus inside a blood vessel obstructs the flow of blood 
through the circulatory system. This blockage leads to a reduction in the blood flow, 
nutrients, oxygen supply and vasoconstriction to an area of cardiac tissue (Bronte-
Stewart et al., 2008), with the most common causes including anaemia and hypotension 
(Libby & Aikawa 2002).  
Overall, the coronary perfusion is reduced. The area of tissue subjected to reduced flow 
in such conditions is referred to as „ischemic‟ tissue and if left untreated, can result in 
cell death. Therefore, it is imperative that intervention be timeously introduced to restore 
muscle function rapidly (Grace 1994, Ovize et al., 1997). 
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Figure 3: A schematic representation of ischemic heart disease. (www.focalcool.com, accessed 2 Aug 
2012) 
1.2 Ischemia Reperfusion (I/R) Injury 
The only way to salvage the heart from ischemia is to restore the blood flow back into 
the ischemic area as quickly as possible (i.e. reperfusion), in order to reduce the 
number of dead cells (forming the infarct) within the myocardium (see Figure 4). 
However, reperfusion has a paradoxical effect: even though blood flow must be 
returned for myocardial salvage it also increases oxidative stress (Yellon & Hausenloy 
2007). Several debate the existence of reperfusion injury nonetheless; reperfusion has 
been deemed lethal because of functional changes, contractile impairment, arrhythmias 
and death to the myocyte (Opie et al., 2004).  
The restoration of blood flow to the tissue results in generation of reactive oxygen 
species (ROS) and calcium overloading (Yellon & Hausenloy 2007; Yellon & Baxter 
1999). Increased ROS promotes the formation of oxygen-free radical derivatives which 
promote endothelial damage. This affects the viable endothelial and myocardial cells, 
and is termed „reperfusion injury‟. It is estimated that reperfusion injury accounts for 
approximately 50% of the infarct after the ischemic insult (see Figure 4) (Yellon et al., 
2007; Prasad et al., 2009).  
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Figure 4: Reperfusion is essential for myocardial salvage. A quicker flow must be returned for myocardial 
salvage (Prasad et al., 2009). 
 
 
Other factors that contribute to reperfusion injury aside from ROS; Firstly, when oxygen 
is supplied to the mitochondria after ischemia there are high levels of calcium in the 
cardiomyocyte. The mitochondria are responsible for the production of adenosine 
triphosphate (ATP) in the cell and calcium handling (Farkas et al., 2008). However, 
there is an imbalance between calcium and sodium exchange at the sarcoplasmic 
reticulum with the return of blood (Kloner et al., 1993). Sometimes, severe damage to 
the pump during myocardial infarction encourages an imbalance between intracellular 
calcium and ATP production. Secondly, during the prolonged ischemia, metabolic 
acidosis is experienced because of anaerobic metabolism and ATP breakdown. The 
sodium/hydrogen pump is activated to restore pH, but simultaneously, the 
sodium/calcium pump is also activated and attempts to remove sodium, which in turn 
causes calcium overload (Piper et al., 1998). Therefore, the rapid restoration of pH 
contributes to muscle contracture and worsened reperfusion injury (Ovize et al., 1997). 
Lastly, the overall normalisation of osmolarity seems to be a key player. It is well known 
that the sodium/calcium pump regulates the volume of water in the cell and osmotic 
load. The osmotic load is increased in both the intracellular and interstitial space and 
the end products of anaerobic metabolism accumulate (Piper et al., 1998; Yellon & 
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Baxter 1999). During reperfusion, an osmotic gradient develops between the 
intracellular and extracellular space. Mechanical stress is increased and sarcolemma 
distribution disrupted in an attempt to restore osmolarity (Piper et al., 1998).  
These events are propagated from cell to cell and eventually lead to the progression of 
necrosis (Garcia Dorado et al., 1997). Therefore, it is critical that reperfusion injury is 
reduced by the use of pharmacological interventions as well as reducing the risk factors 
that contribute to the onset of coronary heart disease (CHD) (see Figure 5).  
 
Figure 5: The role of I/R injury in myocardial infarction (Gracia et al., 2006). 
 
 
If the heart muscle is not reperfused timeously, it can result in permanent damage to the 
myocardium. With extensive damage, the heart will lose optimal function and change in 
size and shape (Gracia et al., 2006). The impaired ability of the heart to pump blood to 
the rest of the body after I/R injury can result in heart failure.  
1.3 Ischemic heart failure 
Heart failure (HF) is a complex clinical syndrome that results from structural and 
functional changes that impair the ability of the heart to pump. The heart struggles to 
support physiological circulation, and there are changes in the peripheral vascular 
function, as well as the myocardial vasculature (McDonagh et al., 2011). These 
changes are necessary to maintain cardiac output and peripheral perfusion. 
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Survivors of a myocardial infarction (MI), even when not complicated, are at a greater 
risk of developing ischemic heart failure (IHF) (Flaherty et al., 2009). Another study also 
showed that in 180 patients that died of HF, myocardial infarction was responsible for 
over 57% of the deaths (Bax et al., 2008). MI-induced HF is a heterogeneous condition 
with several contributing factors, including changes in hemodynamic function, 
neurohormonal abnormalities, loss of function, chamber dilation and left-ventricular 
dysfunction (Chu et al., 2002). The severe loss of cells after MI induces a unique pattern 
of remodelling and promotes left ventricle (LV) thinning. HF continues to progress with 
time, ventricular size increases, and the shape, structure and function of the 
myocardium becomes even more altered (Chu et al., 2002). Myocardial remodelling 
occurs for months until the heart is completely impaired. An aggressive therapy is 
required to ameliorate ischemic heart disease and IHF. 
 
 
Figure 6: The progression from myocardial infarct to heart failure in untreated heart (www.oxford 
journal.org, accessed 4 Aug 2012). 
 
1.4 Cardiovascular (CVD) risk factors  
Classical risk factors for CVD are hypertension, smoking, diabetes mellitus, 
hypercholesterolemia and genetic predisposition (Opie et al., 2006; Kant et al., 1995). 
Hypertension (HPT) is the most common risk factor for both heart failure and IHD in 
Africa, especially among black Africans, as compared to Western countries, which have 
effectively controlled hypertension (Bradshaw et al., 2005) (see Figure 7). 
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 A study performed in South Africa on a cohort of 986 subjects over 15 years showed an 
increased prevalence of high blood pressure by 14.4% in men and 13.7% in women 
(Steyn et al., 1991). It has been postulated that increased urbanisation, including 
changes in healthy diets and reduced physical activity, are potential contributors to 
increased hypertension (Beunza et al., 2010, Mathenge et al., 2010). 
Another risk factor is hyperlipidaemia found in patients with metabolic disorders and 
which are extremely prevalent in developed countries (Mayosi et al., 1998). 
Hyperlipidaemia is characterised by an excess in cholesterol and free fatty acids in the 
blood. There is a definite increase in calorie intake greater than 3000 calories per day, 
predominantly associated with high fats and low fibre intake (Steyn et al., 1991, Hu et 
al., 1997).  
A linear association exists between obesity and a reduction of physical activity (WHO 
2000). Sedentary lifestyles are profound among individuals between 30-39 years, with 
younger people becoming more inactive with time. Other risk factors include diabetes 
mellitus, with type 2 diabetes on the incline by 2.5% in upper- to middle-class countries 
(Podar 2001, Hu et al., 2001), and tobacco smoking, which has declined since 1994 
(King et al., 1998). A sustained high blood glucose level increases the risk of fat 
deposition on the endothelial walls and leads to microvasculature complications 
(Hossain et al., 2007). Alcohol abuse is on the incline, with varying types of alcohol 
consumed including beer, locally brewed beverages and wine bingeing. Alcohol 
bingeing, more than 3 glasses/day increases the risk of HPT, CVD and heart failure (Di 
Castelnuovo et al., 2006). However, several metanalyses display a J-shape curve, 
where the moderate consumption of alcohol (2-3 glasses/day) is protective, but when 
consumed excessively the protective effects are lost (Kozarevic et al., 1993, Collins et 
al., 2009). Potential genetic predisposition may also exist and could increase the 
probability of CVD independently of the risk factors (Rajith et al., 2004).  
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Figure 7: Risk factors that contribute to the development of CVD. (Opie et al., 2006). 
 
1.5 Pathophysiology of ischemic heart disease 
The endothelium maintains normal vascular tone and blood fluidity with little or no 
proinflammatory factors. However, the removal of an obstruction in the heart, such as 
plaque destabilisation predisposes the heart to increased ROS production, elevated 
proinflammatory cytokines and increased apoptosis (Libby et al., 2002).  
When the endothelium is damaged, vasoreactivity is increased due to the chronic 
stimulation of the sympathetic system and reduction in nitric oxide release (NO) 
(Hernandez-Perera et al., 1998). Other studies have shown elevated adhesion proteins 
as well as increased levels of C-reactive protein in heart failure patients (Walter et al., 
2000). Extensive experimental studies in models for diabetes have identified reduced 
NO as the common cause for endothelial dysfunction (Hattori et al., 1999). When the 
endothelium is damaged extensively, it eventually leads to cell death and apoptosis. 
1.5.1 Apoptosis  
After a myocardial infarction, some of the cells survive the prolonged ischemia and lead 
to cell death, morphological changes are distinct and include apoptosis. In general 
apoptosis modulates post-ischemic events and predominantly occurs during the 
reperfusion period, when blood flow is returned to the heart (Bailik et al., 1997, 
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Yamamoto et al., McCully et al., 2004). It is particularly elevated in the ischemic border 
and continues to extend after 12 days post infarction (James et al., 1998). Apoptosis is 
important in the maladaptive process of remodelling and promoted by the activation of 
pro-apoptotic factors like Bax and inhibition the anti-apoptotic factors such as Bcl2, but 
the activation of these factors are dependent on the extent of damage (Lee et al., 2007). 
Therefore extensive damage promotes caspase release and is an important mode of 
programmed cell death in heart failure. 
1.5.2 Necrosis 
Necrosis is generally initialised by non-cellular mechanisms, namely ischemia, trauma 
and thrombosis, all of which lead to irreversible swelling, energy depletion and cell 
death (James et al., 1998). Necrosis is characterised by the reduction in oxygenated 
blood supply to the heart which in turn reduces pH and ATP utilisation (Yamamoto et 
al., 2011) (see Figure 8). DNA fragmentation and internucleosome generation occur 
spontaneously as compared to apoptosis (McCully et al., 2004). Furthermore, necrosis 
is strongly associated with calcium overload that leads to pump dysfunction and cell 
death (Nakayama et al., 2012).  However, it remains unclear whether a distinct variation 
exists between apoptosis and necrosis and whether these events are characterised 
discriminately or merely overlap and complement each other were necessary 
(Yamamoto et al., 2011).  
 
Figure 8: The differentiation between apoptosis and necrosis after ischemia-reperfusion injury (Yamamoto 
et al., 2011). 
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1.5.3 Inflammation  
Excess levels of tumour necrosis factor alpha (TNFα) are frequently released after 
ischemia and increase cell death (Kleinbongard et al., 2010). Furthermore, high levels 
of TNFα are also noted in patients with HF, diabetes, hypertension and atherosclerosis, 
which all promote cell death. The excessive production of TNFα activates the 
uncoupling of the β adrenergic receptor, thus decreasing contractility of the heart, and 
results in cardiac and contractile dysfunction post-ischemia (Gulick et al., 1989). 
Unfortunately, the down regulation of the contractile tissue increases fibrosis and 
collagen deposition, especially in a failing heart (Chen et al., 2008). When the myocytes 
start dying the proinflammatory factors and chemoattractants are released. Muscle 
contraction is altered and results in left-ventricular dysfunction (Chen et al., 2008). 
 
1.5.4 Cellular response to heart disease 
After MI, macrophages, lymphocytes and neutrophils infiltrate the affected myocardium 
within the first few days (Hoshino et al., 1999). The neutrophils enhance the release of 
matrix metalloproteases (MMPs), which, in turn, promote the degradation of collagen 
(Hoshino et al., 1999). Furthermore, the macrophages are mobilised and phagocytose 
apoptotic cells. Initially, contractile activity is increased to compensate for reduced 
cardiac output and this will enhance the activation of intracellular signalling molecules 
including insulin-like growth factor, endothelin, angiotensin-2 and the 
phosphatidylinositol 3 kinase/ protein kinase B (PI3/Akt) pathway to assist the salvaging 
of the myocardium from extensive myocardial damage (Hausenloy et al., 2004). 
 
1.6 Current treatment for heart disease 
CVD cannot be cured, but it can be managed effectively with a combination of lifestyle 
changes and correct drug therapy (Pearson et al., 2002). Drug therapy, angioplasty and 
sometimes surgery are all strategies required to open blocked vessels. Clot formation 
can be prevented by using antiplatelet and anticoagulant agents however, these agents 
are not capable of breaking or dissolving existing clots (Huang et al., 2001).  
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Fibrinolytic agents will dissolve clots rapidly to open the blocked arteries. Plasminogen 
activator administered intravenously can open up to 80% of blocked arteries, but these 
agents must be administered early to achieve maximal success (Staat et al., 2005). A 
more direct approach is percutaneous transluminal coronary angioplasty (PTCA) for the 
opening of blocked coronary arteries. A thin small plastic catheter with a balloon at one 
end is guided to the blocked artery, usually via the femoral artery. The balloon is inflated 
and dislodges the clot. PTCA effectively opens up to 95% of arteries and is used as a 
long-term plan in conjunction with lifestyle changes and pharmacological interventions 
to prevent restenosis (Staat et al., 2007). Most interventional statergies pursued for 
infarcted areteries are PTCA and subsequent stent implantation. Considerable attention 
has been focused on developing novel strategies to attenuate myocardial I/R and to 
improve the myocardium post infarction. 
 
In 1986, the phenomenon of ischemic preconditioning was discovered by Murray and 
colleagues, whereby 4-5 minutes of ischemia followed by intermittent reperfusion was 
induced prior to the prolonged ischemic insult and it was shown to reduce infarct size by 
30% (Murray et al., 1986). Intermittent reperfusion appeared to decrease the adverse 
effects of lethal reperfusion injury (Murray et al., 1986). Given these findings a similar 
protocol was carried out after the prolonged ischemic insult and was subsequently 
termed ischemic postconditioning (Zhao et al., 2003; Mykytenko et al., 2008). The 
protective effects of ischemic postconditioning were comparable to ischemic 
preconditioning (Skyschally et al., 2009; Tsanget al., 1994). Postconditioning reduces 
infarct size in both large and small animals by 30% to 80% (Yellon & Hausenloy 2007). 
Preconditioning and postconditioning are strategies that can be used in a clinical setting 
to treat against MI and HF. Interestingly, there are multiple intrinsic survival pathways 
that can be deployed to salvage the heart after I/R injury. 
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2 Intrinsic cardiac prosurvival pathways 
2.1. Reperfusion injury salvage pathway 
The reperfusion injury salvage (RISK) pathway involves the activation of 
phosphoinositidol kinase (PI3K), protein kinase B (Akt), extracellular regulated kinase 
(ERK), mitogen extracellular kinase (MEK) and glycogen synthase kinase (GSK), which 
are capable of protecting against I/R injury (Yellon et al., 1999; Hausenloy et al., 2004). 
The activation of this pathway will result in the closing of the mitochondrial permeability 
transition pore (mPTP) (Juhaszvoa et al., 2004). It has been suggested that the 
PI3K/Akt and ERK can be activated prior to the ischemic insult as well as at the onset of 
reperfusion to confer cardioprotection (Omura et al., 1999). Therefore, the early 
activation can act as a primer for kinase phosphorylation at the onset of reperfusion 
(Hausenloy et al., 2005). Interestingly, the inhibition of PI3K/Akt with wortmanin or 
LY294002 in the isolated rat heart increases infarct size (Tsang et al., 2004). Similarly, 
inhibition of MEK/ERK 1/2 pathways with PD98059 increased infarct size after I/R injury 
(Yang et al., 2004). By 2007, some of the intermediate targets for the RISK pathway 
that were identified are protein kinase G (PKG), protein kinase C (PKC) and glycogen 
synthase kinase-beta (GSK3β) (Hausenloy et al., 2007). 
The endpoint for the RISK pathway is thought to be the inhibition of the opening of 
mPTP. The structure of this mPTP still needs to be delineated but its opening results in 
the release of cytochrome C from the mitochondria, leading to apoptosis (Hausenloy et 
al., 2004). Recently, it has been suggested that there are other alternative pathways 
that also protect the heart, such as the survivor activating factor enhancement (SAFE) 
pathway.  
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Figure 9: Activation of the RISK (reperfusion injury salvage kinase) pathway for myocardial salvage. 
Opiods and adenosine activate the RISK pathway with either PI3K/Akt (phosphoinositol kinase)/protein 
kinase B or MAPK/ERK (mitogen activating kinase/extracellular kinase) activation which in turn target the 
mitochondria as the endpoint to confer cardioprotection (Gross & Auchampach. 2007) 
 
2.2. Survivor Activating Factor Enhancement (SAFE) pathway 
Another key prosurvival pathway is the SAFE pathway (Lecour et al., 2009). The 
constituents are TNFα, which initiates the activation of the innate immune system and 
the well-known protective signaling molecule, signal transducer and activator of 
transcription 3 (STAT3).  
  
2.2.1. TNF alpha and its role in the SAFE pathway  
The first line of defence after an ischemic insult is the activation of the innate immune 
system. It is an adaptive process that mobilises the infiltration of cytokines such as 
TNFα (Kleinbongard et al., 2010). Several studies have demonstrated the pleiotropic 
effects of TNFα, exhibiting protective qualities at low concentrations and detrimental 
effects at higher concentrations (Lecour et al., 2002).  
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However, the good versus the bad effects of TNFα are not only concentration-
dependent but also receptor-dependent (Lacerda et al., 2009; Lecour et al., 2002).  
There are two types of receptors: TNFα receptor 1 (TNFR1) and TNF receptor 2 
(TNFR2) (Baxter et al., 1999). Receptor stimulation is dependent on other inflammatory 
cytokines, including interleukin-1 (IL-1), IL-10, IL-4 and growth factors (Manna et al., 
1998). TNFα binds to either receptor in a dose- and time-dependent manner (Deucher 
et al., 2007) (see Figure 10). When bound to TNFR1 it stimulates activation protein-1 
(AP-1), IK beta complex (IKK) which, in turn, activates nuclear factor kappa B (NFKB) 
(Haudek et al., 2001). NFKB regulates the inflammatory response and further increases 
the release of TNFα (Haudek et al., 2001). The continuous stimulation of TNFR1 
propagates the activation of pro-apoptotic factors like JNK and exacerbates the effects 
of MI, HF and atherosclerosis (Dorg et al., 2002, Kin et al., 2008). However, the 
outcome after activation of TNFR2 is vastly different. 
TNFR2 is activated by inflammatory cytokines and growth factors, but its response is 
mediated via the activation of Janus Kinase 2 (JAK2), which in turn, phosphorylates and 
activates the signal transducer and activator of transcription (STAT3) (Frias et al., 2009; 
Lacerda et al., 2009). In addition to this, TNFR2 also stimulates PI3/Akt and ERK 
prosurvival signalling molecules (Kleinbongard et al., 2010). Interestingly, the inhibition 
of TNFR1, with specific antibodies, in both rabbits and dogs, increases infarct size after 
I/R injury (Dorge et al., 2002). However, the complete inhibition of TNFα has led to 
controversial data, in one study there was a reduction in infarct size after ischemia-
reperfusion injury, in TNF-deficient mice. On the contrary, another study showed that 
mice without TNFα were worse off compared to their wild-type littermates (Dawn et al., 
2004; Labruto et al., 2005). Hence the presence of TNF, even in small quantities, is 
necessary for heart function (see Figure 10). In 2002, the exogenous administration of 
TNFα at low concentration prior to the prolonged ischemia conferred cardioprotection in 
an isolated rat heart model (Lecour et al., 2002). Other experiments demonstrated that 
the low concentration of TNFα improved mitochondrial respiration and reduced 
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mitochondrial swelling; and suggested that the protective effect of TNFα may be 
mediated via the transient closure of the mPTP (Lacerda et al., 2010). 
 
Figure 10: The pleiotropic effects of TNFα (tumour necrosis factor) in protecting against I/R. (Lecour 
2009). 
 
2.2.2.  STAT3 and its role in the SAFE pathway 
STAT3 is one of seven STAT isoforms found in the heart (Soon et al., 2006). STAT-1 
and STAT-3 (Xuan et al., 2001; Yang et al., 2008), have opposing effects; STAT-3 
activation is antiapoptotic and STAT-1 activation proapoptotic (Hilfiker-Kleiner et al., 
2004). Mice with STAT3 depleted in the cardiomyocytes eventually develop heart failure 
(Hilfiker-Kleiner et al., 2004; Jacoby et al., 2003). 
In the SAFE pathway, TNFα binds to its receptor 2 which leads to the activation of 
STAT3 after the ligand binding of Janus Kinase 2 (JAK), a tyrosine kinase, see figure 
11. It is postulated that the activation of JAK may promote the phosphorylation of 
STAT3 on the tyrosine residue (Xuan et al., 2001). STAT3 then homodimerises and 
translocates from the cytosol to the nucleus, where it is further phosphorylated on a 
serine residue 705 (pSTAT) and becomes activated as a transcription factor for 
prosurvival genes such as manganese superoxide dismutase (MnSOD) and inducible 
Nitric Oxide Syntha se (iNOS) (as reviewed by Boengler et al., 2008a; Boengler et al., 
2008b ).  
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Figure 11: The role of the SAFE pathway in myocardial salvage. Cytokine, TNFα binds to its receptor and 
in turn, activates JAK which leads to the activation and translocation of STAT3 from the cytosol to nucleus 
or the mitochondria pathway).IL (interleukin) Gp 130 (G coupled protein receptor), soc (suppressor 
cytokine signaling). (Lecour & James. 2011). 
 
 
The presence of STAT-3 in the mitochondria has recently been discovered, leading to 
the updated pathway which proposes that the location of STAT-3 phosphorylation may 
determine its fate (Mykytenko et al., 2008, Bolli et al., 2001). Furthermore, recent 
evidence has suggested that STAT-3 may not even need to be phosphorylated or 
dimerised in order to enter the nucleus, although tyrosine phosphorylation is still 
required for transcriptional activity (Liu et al., 2005). Thus, in the new model pSTAT 
bound on the tyrosine residue translocates to the nucleus and acts as a transcription 
factor, while pSTAT bound on the serine translocates to the mitochondria (Liu et al., 
2005), where it promotes cell survival, most likely via mPTP activation (Boengler et al., 
2008b) has an anti-apoptotic effect; however, more studies are required (Liu et al., 
2005). Nonetheless, it is clear that STAT3 is a powerful signalling molecule that is 
activated to protect the heart and is closely integrated in the SAFE pathway.There are a 
variety of agents that activate STAT3 such as insulin (Fuglesteg et al., 2008), 
ethanolamine, a component of red wine (Kelly et al., 2010), sphingosine-1-phosphate, a 
component of HDL (Somers et al., 2011) and interleukin 6 (Kurdi et al., 2007), an 
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inflammatory cytokine. Another potential activation of the SAFE pathway is red wine and 
its cardioprotective compounds, see figure 12. 
?
?
 
Figure 12: Several components stimulating the SAFE pathway. (Lecour & James 2011). 
 
3. Red wine and cardioprotection  
Daily moderate consumption of red wine is associated with reduced cardiovascular 
events compared to those who abstain or binge-drink (WHO 2002). Drinking wine with 
food may also be of benefit as it slows the absorption of ethanol (Kozarevic et al., 
1983). 
3.1 The history of red wine 
Wine describes a class compound of yeast fermentation pressed from grapes, from the 
genus Vitis (Murche et al., 2010). Interestingly, wine can be traced back to the ancient 
civilization with the earliest known production in 4500BC in ancient Greece, Thrace and 
Rome (Berkowitz et al., 1996; Soleas et al., 1997). Red wine has been a socioreligious 
symbol for decades and is believed to have magical medicinal value. The benefit of red 
wine was first proposed by the father of medicine, Hippocrates of Kos in Greece, and 
was not researched for many years (Soleas et al., 1997).The interest in the protective 
qualities of red wine re-emerged in 1992 as an extremely well-researched topic, after 
epidemiological studies tantalised the world with the premise that moderate red wine 
consumption could offer cardioprotection (St Leger et al., 1992). 
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3.2 The French paradox 
In France, wine traces back to the 6th century BC, and over 50-60 million hectolitres of 
wine are produced per year (Berkowitz et al., 1996). During the Middle Ages some of 
the best vineyards were conserved and maintained by monks for celebrations and 
generating a steady income during turbulent times. As time progressed, it became a 
social grace to drink wine and many vineyards were later owned by nobility (Berkowitz 
et al., 1996). In France, wine consumption is clearly a part of their national heritage and 
an important part of their culture that is valued, nurtured and rarely observed consumed 
in excess or as binge-drinking. Therefore, it is easy to understand that the French 
habitually drink wine with their meals.  
Epidemiological studies demonstrate a strong inverse association between moderate 
red wine consumption and CVD in France when compared to other European countries, 
North America and Australasia (St Leger et al., 1979). Even though the French 
consume foods which are saturated in fat, the risk of CVD is reduced compared to other 
Westernised countries (see Figure 13). A possible reason is the regular consumption of 
red wine with meals. This observation was consequently termed as the French paradox 
(Renaud et al., 1992).  
 
Figure 13: The French paradox. The French population has a lower risk of coronary heart disease even 
though the cholesterol intake is high (Ferrieres et al., 2004). 
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A study conducted in more than 36 000 men in the eastern part of France between 
1978 and 1983, demonstrated that men drinking between 2 to 3 glasses/day of red wine 
had 30% fewer deaths from all-cause mortality compared to non-drinkers or  excessive 
drinkers (that drank more than the prescribed, 2-3 glasses/day) (Renaud et al., 1999). 
Klatsky reported that moderate alcohol consumption from whatever source reduced the 
risk of CVD compared to teetotallers (Klatsky et al., 1993).  
These studies were further corroborated by Kannel and Eddison, who also found that 
moderate alcohol consumption improves cardiovascular outcome (Kannel & Eddison 
2007; Doll et al., 2007). Interestingly, those that consumed red wine had a superior 
cardioprotective effect compared to other alcoholic beverages in reducing CVD (Doll et 
al., 2007).  
However, these epidemiological studies need to be interpreted with caution as 
differences in alcohol consumption may also reflect differences in nutritional intake, 
lifestyle and behaviour (Empana et al., 2011). Indeed, regular wine drinkers consume 
more fruits, salad, vegetables, fish and olive oil (Tjonneland et al., 1999). Also, wine 
drinkers exercise more, smoke less and they have a higher level of education than non 
wine drinkers (Mukamal et al., 2005). 
3.3 Red wine confers cardioprotection 
In survivors of a first MI, the association between red wine intake and the risk of 
recurrence of MI during a four-year follow-up demonstrated a reduction of the adjusted 
risk of cardiovascular complications by 59% in patients, drinking an average of four 
glasses per day (De Lorgeril et al., 2002). A metanalysis of 51 studies concluded that 
moderate red wine consumption reduced the risk of CVD by 20% (Smitko et al., 2005). 
Furthermore, regular red wine consumption improves the outcome of both MI patients 
and diabetic patients.  
In animal models very few studies have demonstrated wine that has been administered 
r on its own to determine its protective effect. The only experimental studies to date that 
compared the differences in red wine vs. white wine in an isolated heart model 
demonstrated that the cardioprotective effects of white wine were mediated by the 
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presence of the polyphenols tyrosol and hydroxytyrosol (Dudley et al., 2008). However, 
this study has been withdrawn from Pubmed due to fraudulent activity.  
 Most studies have administered either alcohol or polyphenol extracts independently 
(Das et al., 1999).Therefore, the key attributes of red wine are unclear; it may be the 
alcohol and the polyphenol content or a synergy of the two that promote the protective 
effect of red wine, which remains elusive.  
3.4 Mechanisms for red wine-induced protection  
3.4.1 Anti-oxidant effect 
Red wine has a variety of attributes: it is an anti-oxidant, reduces low-density 
lipoproteins (LDL) oxidation, and improves cytokine release and eicosanoid response 
thereby reducing inflammation (Handelman et al., 1993). It is believed that the 
polyphenol content in wine permits its anti-oxidant ability (Frankel et al., 1993). Red 
wine scavenges free radicals both directly and indirectly. The polyphenols in red wine 
facilitate reduced hydrogen peroxide (H2O2) formation by quenching the electronically 
excited compounds (Rodrigo et al., 2011). After the consumption of 300mℓ of wine, the 
anti-oxidant capacity in human plasma increased to 18%, an effect was comparable to 
the effect of vitamin C (Rodrigo et al., 2011). In human studies, both the anti-oxidant 
qualities of regular moderate consumption of white, rose and red wine was assessed 
(Coimbra et al., 2005). The findings demonstrate strong anti-oxidant ability in red wine 
when compared to the other beverages. In addition to this the production of H2O2 and 
phospholipase C diminished after red wine consumption (Tozzi Ciancarelli et al., 2011). 
Red wine prevents the accumulation of the by-products (such as malonaldehyde and 
hydroxyl ions) from lipid peroxidation and improves the endothelial function (Tozzi 
Ciancarelli et al., 2011). 
3.4.2 Vascular effect 
Vascular endothelial function plays a crucial role in the pathogenesis of atherosclerosis. 
The structural integrity and function must be maintained by promoting factors such as 
endothelin-1 (ET-1, vasoconstrictor) and plasminogen inhibitor 1 (PAI, vasodilator) 
(Kiviniemi et al., 2010). Furthermore, the consumption of red wine suppresses ET-1 and 
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induces vasorelaxation in the blood vessels (Kiviniemi et al., 2010, Crozier et al., 2011). 
Red wine improved coronary flow velocity (Shimada et al., 2010). Furthermore, the 
polyphenols present in red wine prevented the migration of oxidised LDL to the 
macrophages thereby, limiting both the progression and formation of plaque (Maxwell et 
al., 1994). Red wine also inhibits the NFkB in the mononuclear cells and in human cells 
(Pellegatta et al., 2003) as well as the migration of monocyte chemotactic protein (MCP-
1) and vascular smooth muscle cells to the intima (Pellegatta et al., 2003). Thus red 
wine displays strong antithrombotic action. In the Health Physicians study, light to 
moderate drinkers had a reduced fibrinogen (which is synthesised in the liver to reduce 
coagulation) reduced Von Willebrand factor (key glycoprotein involved in haemostasis) 
and diminished fibrinogen activator (Mukamal et al., 2001).  
3.4.3 Anti-platelet effect 
Platelet aggregation is the clustering together of thrombocytes to prevent bleeding. The 
formation or presence of a blood clot in a blood vessel is termed a thrombus. In the ex 
vivo assessment of platelet response in healthy patients, red wine inhibited platelet 
aggregation mediated by the presences of the polyphenols. Thromboxane, produced 
from arachadonic acid in the eicosanoid pathway and 5-lipoxygenase, was also reduced 
Tozzi Ciancarelli et al., 2011). E-selectin and IL-6 were increased after red wine 
consumption and may have an effect on lipid responsiveness by improving the 
hemostatic profile (Tozzi Ciancarelli et al., 2011). In addition, aggregation in response to 
adenosine diphosphate (ADP) and thrombin in human platelets is strongly inhibited by 
red wine (Pace-Asciak et al., 1993). Other studies debate whether it is the polyphenol 
content in the wine or the ethanol content that explains the decrease in platelet 
aggregation (Soleas et al., 1997).  
3.4.4 Anti-cholesterol effect 
Regular consumption of red wine reduces LDL, also commonly termed, the “bad 
cholesterol” decreases lipid peroxidation and increases plasma concentration of high 
density lipoproteins, HDL also commonly termed the “good cholesterol” (Frankel et al., 
1993; Kaplan et al., 2004). In addition, the red wine modified and enriched the 
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composition of HDL in polyunsaturated phospholipids such as omega-3 fatty acids, 
which are said to be beneficial against coronary artery disease (Perret et al., 2002, 
Fabrizio et al., 2007). 
In hypercholestrolemic rabbits, the chronic moderate consumption of red wine improved 
flow-mediated dilatation (FMD) and increased the release of nitric oxide (NO) (Wallerath 
et al., 2003). Thus red wine consumption mitigates the effects of a high-cholesterol diet. 
Clinical studies conducted in patients with metabolic syndrome assessed red wine 
intake with a questionnaire and then assessed lipid profile. In these patients a glass of 
red wine a day reduced the triglyceride and total cholesterol level (Davis et al., 2002).  
 
3.5 The role of alcohol and red wine-induced cardioprotection 
There are more than 1000 compounds present in red wine, but alcohol and polyphenols 
are thought to be the major contributors to the protective effects of red wine. The 
production of red wine is from an assortment of grape cultivars, under varying climatic 
conditions in different geographical locations. The grapes have different maturity levels 
for vinification and ageing. Therefore, red wine is extremely heterogeneous in chemical 
composition, flavour, taste and appearance. The extraction process for red wine is 
prolonged with extensive fermentation. The fermentation process increases the phenolic 
content by 40-60% (Crozier et al., 2011). Ageing and maturity of the wine is further 
enhanced when stored in an oak barrel, which can also contribute to improving the 
phenolic content (Jimenez-Moreno et al., 2003, Iriti et al., 2010). In white wine, the 
phenolic yield is reduced compared to red wine, due to the removal of grape skins 
during the winemaking process. The alcohol content in red wine is crucial for the 
stability, ageing, and gustatory properties of the wine. It plays a role in the extraction of 
pigments and tannins during the fermentation of the skin and seeds of grapes (Das et 
al., 1999). Red wine consists of 81% water, 12% alcohol, 1% sugar, 5% sulphites, 1% 
grape thaumatin, 1.5% acid (i.e. gallic acid), 1% vitamins, 1% minerals and 1% phenolic 
compounds.  
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It is surprising that the phenolic content is so low, but this will differ from wine to wine 
and also emphasises the importance of the fermentation process as well as the synergy 
of all the compounds in red wine that contribute to its cardioprotective effect. 
3.5.1 Alcohol-induced health benefit 
Several epidemiological studies including, the Framingham study and Copenhagen City 
Heart trial, have shown that there is a consistent inverse relationship between alcohol 
consumption and mortality, whereby a low to moderate consumption of alcohol during 
meals promotes beneficial effects (Hulley et al., 1981). However, the excessive 
consumption of alcohol or binge drinking has a linear association between the drinks 
consumed and increases the risk of mortality and disease (Gordon & Kannel 1984; Doll 
et al., 1994; Thun et al., 1997) and the alcohol effect can be described as a J-shaped 
curve (see Figure 14). It is recommended for men and women to have 1 to 3 glasses of 
alcohol per day to confer cardioprotection and teetotallers have neither an increased nor 
a decreased risk of CVD (Thornton et al., 1983).  
 
Figure 14: The J Shape mortality curve. 1-3 glasses per day reduces relative risk of mortality (Keefe et al., 
2007 ).  
 
In a multinational study, lack of alcohol intake increased risk factors for Type 2 diabetes, 
emphasising that cardioprotection conferred from alcohol consumption affects 
triglycerides and insulin levels (Hu et al., 2001).  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 26  
 
However, the cessation of alcohol will result in the loss of all beneficial effects within 24 
hours (Jackson et al., 1992). Klurfield et al. compared different alcoholic beverages, 
including beer, white wine, red wine, whiskey and ethanol on its own, and found that red 
wine conferred cardioprotection to a greater extent and its beneficial properties were 
deemed superior compared to the other beverages (Klurfield et al., 1981).  
3.5.2 The alcohol protects against I/R 
Regular moderate consumption of alcohol from whatever source can confer 
cardioprotection. The health professionals‟ study suggested that 2-3 drinks per day 
reduce the risk of MI (Mukamal et al., 2003). Similar data were obtained in the 
physicians‟ health study, which showed reduced risk of CVD with alcohol consumption 
(Cramargo et al., 1997). In the Framingham cohort the risk for congestive heart failure 
was reduced relative to alcohol intake (Cramargo et al., 1997). However, whether one 
alcoholic beverage had superior protection remained elusive. Experimentally, mice 
drinking water supplemented with ethanol ranging between (2.5-36%) for six weeks, 
showed profoundly reduced infarct size after I/R ex vivo. The heart‟s recovery was 
improved and creatin levels reduced (Jackson et al., 1992). 
Acute ethanol (10mM) administration 20 minutes prior to I/R reduced infarct size and 
conferred protection ex vivo (Fuchs et al., 2007). On the contrary, 0.8 g/kg administered 
20 minutes prior to I/R did not reduce infarct size and there was no hemodynamic 
variation in vivo (Rakotovac et al., 2004). These results are well supported in the 
literature and further demonstrated that the protective effect of ethanol was lost at high 
concentrations, thus the cardioprotective effect of alcohol is dose-dependent 
(Rakotovac et al., 2004). In these studies, moderate alcohol consumption-sustained 
cardioprotection required the activation of the mitochondrial potassium adenosine 
triphosphate (KATP) channels, as reviewed by (Collins et al., 2009). Mice treated with 
10% alcohol for 12 weeks protected the hearts against I/R injury via the activation of NO 
(Zhou et al., 2002b). Similarly, rats that were treated with 18% alcohol for eight weeks in 
drinking water improved post-ischemic systolic and diastolic pressure and it also 
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increased cardiovascular resistance via the activation of protein kinase C (PKCε), see 
review (Collins et al., 2009).  
 
3.6 Does alcohol contribute to red wine induced cardioprotection  
Healthy patients younger than 40 years were divided into two groups: red wine with or 
without alcohol (Agewall et al., 2000). Acute red wine ingestion (250mℓ) increased blood 
flow and heart rate. After the acute ingestion of dealcoholised red wine there was an 
increase in the flow-mediated dilation in the brachial artery, but not the other 
hemodyanamic parameters (Agewall et al., 2000). Many speculate that purple grape 
juice may have similar effects to dealcoholised red wine. In hypercholesterolemic 
subjects that received 250mℓ of red wine vs. 500mℓ of grape juice for 14 days, the flow-
mediated dilation was improved in both red wine and grape juice drinkers compared to 
placebo controls (Fremont et al.,1999). However, red wine significantly increased 
endothelium-independent vasodilation. Grape juice reduced intracellular adhesion 
molecule (ICAM) but this effect was not observed with red wine consumption on its own. 
Therefore, hypercholesterolemic patients exhibit improved vasodilation after red wine or 
grape juice consumption (Coimbra et al., 2005). In humans, supplementation with grape 
juice promotes endothelial relaxation and inhibits LDL oxidation (Vinson et al., 2001).  
Experimentally, hyperlipidemic mice fed on grape juice, red wine or dealcoholised wine 
had significantly higher HDL levels compared to the ethanol groups or water controls 
(Dai et al., 1997). Furthermore, experimental studies performed during research for my 
Masters degree demonstrated that red wine with a reduced alcohol content (from 12% 
to 6%) still conferred cardioprotection to a similar extent as the unaltered red wine 
(Lamont et al., 2012). Therefore, red wine-induced protection goes beyond the alcohol 
content and may be attributed to other components, such as polyphenols.  
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3.7 Resveratrol and red wine 
Resveratrol (3,4,9,5 trihydroxy-trans-stilbene) is a common phytoalexin produced in 
response to stress in specific plants (see Figure 15 below). It is present in several foods 
such as grapeskins, peanuts, strawberries and red wine (Mukherjee et al., 2009). 
 
 
Figure 15: Schematic  presentation of the chemical structure of resveratrol (own drawing). 
 
 
Resveratrol exhibits a wide range of biological and pharmaceutical properties. It 
promotes vasodilation via nitric oxide activation (Wong et al., 2011), inhibits platelet 
aggregation, increases HDL cholesterol (Wang et al., 2005) and therefore serves as a 
strong cardioprotective agent. These properties have propelled a great interest in the 
health benefit of resveratrol found in wine. It has been speculated that high resveratrol 
levels in red wine (in comparison to other beverages) may be responsible for its 
cardioprotective effect. The concentration of resveratrol in the grape is dependent on 
the type of grape used and can range from 0.1-14 mg/mℓ of fresh weight (Bertelli et al., 
1998). 
The consumption of half a bottle of Brazilian red wine containing the stilbene resveratrol 
at a concentration of 11mg/mℓ would result in a blood concentration of between 4µM 
and 10µM (Bertelli et al., 2002). The concentration of 10µM is the minimum resveratrol 
concentration required to exert a biological effect in vitro (Pellegatta et al., 2003).  
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3.7.1 Resveratrol confers cardioprotection  
Preconditioning the heart with resveratrol (10µM = 2.3 mg/ℓ) improves post-ischemic 
ventricular recovery, reduces infarct size and decreases cardiomyocyte apoptosis 
(Hattorri et al., 2002).The administration of resveratrol (10µM), 30 minutes prior to I/R, 
protects the heart via increased expression of adenosine A1 and adenosine A2 receptors 
(Das et al., 2005).  
Resveratrol modulates prosurvival-signalling pathways and activates antiapoptotic 
molecules like Bcl2, Akt and the forkhead transcription factors (FOXO) after I/R injury 
(Das et al., 2005).  
Furthermore, resveratrol promotes the translocation of Bax, the propapoptotic factor and 
reduces the release of cytochrome c and caspase 8 from the mitochondria (Xi et al., 
2009). The activation of these pathways is dose-dependent.  
Interestingly, the protective effect of resveratrol can only be observed at low doses 
between (2.5 - 5mg/kg/ day) with an improvement in post-ischemic ventricular function 
(Das et al., 2006). A high dose of resveratrol (50mg/kg) deteriorates heart function and 
increases infarct size (Das et al., 2005). On the other hand, in cancer cells, resveratrol 
at a high concentration also promotes a death signal, which is of benefit in this 
pathology (Das et al., 2005). Therefore, resveratrol (at varying concentrations) activates 
diverse pathways which affect different pathologies. In cardioprotection, a low 
concentration of resveratrol is preferred and can be well correlated with the notion that 
red wine is only cardioprotective with regular moderate consumption.  
Resveratrol has pleiotropic effects that can be extended to a variety of pathologies. In 
the brain, chronic resveratrol (30mg/kg) treatment improves brain metabolism, 
increases glucose, ATP and increases energy exchange after I/R injury. Furthermore, 
resveratrol increases neuroprotective agents such as adenosine, inosine, hypoxanthine 
and xanthine (Dong et al., 2008). Therefore, even in a neurological model, resveratrol 
protects effectively against IR injury (Dong et al., 2008). 
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3.7.2 Resveratrol may improve the effects of heart failure (HF) 
The major risk factors contributing to HF are hypertension, diabetes , obesity and 
coronary heart disease (Dong et al., 2008; Das et al., 2010). Early resveratrol 
administration reduces these effects in several studies (Dong et al., 2008; Das et al., 
2010). Interestingly, resveratrol treatment improves vascularisation in the infarcted 
myocardium via the activation of thioredoxin (TRX) (Hoshino et al., 2007). Resveratrol 
(10 µM) regulates TRX and activates anti-apoptotic, anti-inflammatory pathways via 
hemeoxygenase-1 activation, thus the activation of TRX may reduce the effects of HF 
and cardiomyopathy (Hoshino et al., 2007).  
Pathological left-ventricular hypertrophy (LVH) is a devastating condition that increases 
susceptibility to IHD and HF. LVH is characterised by increased myocardial mass 
modulated by the prohypertrophic pathways such as liver kinase B1/ adenosine 
monophosphate (LKB1/AMP)-activated protein kinase (AMPK). Chronic resveratrol 
administration (2.5mg/kg/daily) inhibits LKB1/AMPK signaling and activates mammalian 
target of rapamycin (mtor) and p-70ribosomal s6kinase (p70S6K) thereby, reducing the 
effects of LVH (Dong et al., 2008). Therefore, resveratrol treatment presents as an 
adjunct therapy for patients and may lessen the risk of IHD and HF. 
Experimentally, the direct impact of resveratrol on HF in vivo demonstrates that 
resveratrol (10uM) suppress the progression of HF via the activation of the longevity 
protein sirtuin1 an effect that and may be attributed to the upregulation of MnSOD via 
FOXO3a activation (Chui et al., 2010 ISHR abstract).  
 
3.8 Mechanisms for resveratrol   
3.8.1 Resveratrol and its anti-oxidant properties 
Resveratrol is a potent scavenger for intracellular reactive oxygen species (ROS) (Bhat 
et al., 2002), see Figure 16. Although it possesses anti-oxidant properties in vivo, it is a 
weak scavenger in vitro (Bhat et al., 2002). This anti-oxidant effect could explain the 
inhibition of LDL oxidation (Frankel et al., 1993).  
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Resveratrol has a very high binding affinity for VLDL and LDL. At the onset of 
administration, it scavenges the free radicals in an aqueous solution and then traps the 
polyunsaturated fatty acids within the membrane. It prevents lipid peroxidation by 
chelating copper and not iron, thereby accelerating the removal of copper from LDL 
particles without affecting iron absorption in the microsome (Fremont et al., 1999). 
Moreover, resveratrol reduces the formation of thiobarbituric acid-reactive substance 
and has a strong inhibitory effect on the superoxide radicals and H202 produced by the 
macrophages (Frankel et al., 1993).  
After the administration of resveratrol to aortic endothelial cells, the production of 
reactive oxygen species (ROS) from polymorphonuclear leukocytes (PMN) is fully 
segmented (Leonard et al., 2003). Granulocyte with lobes in the nuclei are reduced, as 
well as the release of elastase and b-glucuronidase. For adhesion-mediated function 
PMN must bind to b2 intergrin MAC-1, but this binding is prevented with resveratrol 
administration (Pellegatta et al., 2003). Furthermore, resveratrol inhibits both the 
intracellular adhesion molecule (ICAM) and the vascular adhesion molecule (VCAM) via 
the activation of NFkB, an indirect marker for oxidative stress, in the presence TNFα 
(Ferrero et al., 2003).  
3.8.2 Resveratrol and endothelial function 
Resveratrol protects the myocardium against I/R, in both an in vitro and in vivo setting  
via NO activation, see figure 16 (Hattorri et al., 2002, Wallerath et al., 2003). However, 
resveratrol fails to protect in NO-deficient mice against I/R injury (Hattorri et al., 2002, 
Wallerath et al., 2003). Clinically, impaired FMD in the brachial artery is characterised 
by the loss in the endothelial dependent vascular smooth muscle, increased oxidative 
stress and eNOS uncoupling (Wong et al., 2008) (see Figure 16) In experimental 
studies resveratrol promotes vasorelaxation via the activation of NO and improves FMD 
(Bhatt et al., 2011). In a study, a sample size of 40 obese patients with a body mass 
index (BMI) between 25 and 35 were separated and treated daily with varying doses of 
resveratrol tablets (0, 30, 90, 270 mg). 
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The findings demonstrate that in obese patients daily consumption of resveratrol 
improves flow-mediated dilatation in a dose-dependent manner (Wong et al., 2008). 
Interestingly, a tablet that optimises the absorption and bioavailability of resveratrol has 
been developed to improve its natural effect at a lower concentration (Fujitaka et al., 
2011). 
Hence, Longevenix is a modified resveratrol microcapsule in plant starches and 
dextrins, used to prevent phytoisomerisation and therefore improves resveratrol half-life. 
The tablet consists of 100 mg resveratrol, vitamin D3 and quercertin (Fujitaka et al., 
2011). Longevenix was administered to 34 patients that were diagnosed with the 
metabolic syndrome and were already on standard treatment (ACE inhibitors, 
angiotensin receptor ‖  blockers and statins) (Fujitaka et al., 2011). In conjunction with 
this, Longevenix was administered for three months and stopped for three months to 
determine whether the effect persists. There were no changes with blood pressure, 
HDL, LDL or BMI. However, a prominent increase in FMD was displayed after the three 
months but not sustained. Thus the study supports the notion that resveratrol improves 
endothelial function (Fujitaka et al., 2011), activates NO, but its effect on hypertension, 
a major contributor to vascular disease and oxidative stress, is unknown.  
Recently, an experimental study demonstrated that resveratrol (50mg/ℓ), given in the 
drinking water of rats) improves endothelial function and attenuates the rise in blood 
pressure in hypertensive rats (Pellegeta et al., 2003). Furthermore, the early chronic 
treatment of resveratrol prevents e-NOS uncoupling, reduces H2O2, and improves the 
percentage change of relaxation in the mesenteric artery rings (Bhatt et al., 2011). It has 
been reported that the vascular oxidative stress precedes development of hypertension 
in spontaneous hypertensive rats (SHR) (Nabha et al., 2005). The study highlights the 
importance of early resveratrol treatment in reducing the effects of endothelial 
dysfunction. Overall, resveratrol prevents eNOS uncoupling and endothelial dysfunction 
and attenuates the development of hypertension, a major contributor to IHD and HF. 
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Figure 16: Cardioprotective actions of resveratrol (adapted from Vidavavular et al., 2009). 
4 Melatonin Structure and Function 
Melatonin (N acetyl-5-methoxytryptamine) is synthesised by the pineal gland and 
regulates circadian rhythm (Cajochen et al., 2003). It is involved in multiple processes 
(Tan et al., 1993) and has been suggested to have strong anti-oxidant, anti-
inflammatory, vascular and anti-ischemic effects. However, melatonin capsules are 
freely available and are commonly used for jet lag and insomnia (Cajochen et al., 2003, 
Singh & Kumar 2009).  
 
 
Figure 17: Schematic presentation of the chemical structure of melatonin (own drawing). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 34  
 
4.1 Melatonin and biosynthesis  
Melatonin is produced in several tissues including, the pineal gland, retina, lens and 
gastrointestinal tract (Dowling et al., 2005). Melatonin is both lipid and water soluble 
which easily facilitates its movement across the cell membrane. After its release, it 
gains access to various tissues and cellular components (Galli-Carminati et al., 2009).  
It is synthesised from the amino acid tryptophan (via synthesis of serotonin). Serotonin 
is converted to melatonin in the presence of N-acetyltransferase and s-acetylserotonin-
O-methyltransferase (ASMT) (Lane & Moss 1985). Its production by the pineal gland is 
regulated by the hypothalamus which receives information from the retina about the 
daily pattern of light and darkness (Dowlin et al.,2005). Light suppresses the production 
of melatonin while darkness stimulates its production. Exposure to excessive light in the 
evening or too little light during the day can disrupt the body‟s normal melatonin cycle. 
Melatonin levels oscillate from 40 pg/mℓ during the day to 80 pg/mℓ at night (Hardeland 
et al., 2003). The exogenous administration of melatonin (supraphysiological levels), for 
jet lag or insomnia, does not interfere with the normal production of melatonin.  
Of note, there are no studies that demonstrate melatonin toxicity even at higher 
concentrations and this encourages its clinical use without side effects (Jahke et al., 
1999).  
 
4.2 Melatonin and its receptors 
Melatonin is mediated via its G-coupled protein receptors. Melatonin receptor 1 (MT1) 
and 2 (MT2) are G-coupled protein receptors. These receptors have a distinct encodes 
the Gprotein receptors, aspartic (NRY motif) rather than a conserved amino acid 
glutamic/aspartic (DRY motif). The receptors are glycosylated in their N-terminus. PKC, 
casein 1, 2 and PKA participate at the regulation of the receptor (Rodriguez et al., 
2004). The activation of the MT1 or MT2 facilitates the dissociation of alpha (α) and 
beta-gamma (βγ) dimers from the G-coupled protein receptor (Ekmekcioglu et 
al.,2001)..  
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MT1 regulates the rhythmicity of the circadian clock expression via the activation of 
adenylycyclase which in turn, inhibits cβ fibre activation in the hypothalamus (Hattori et 
al., 1998). The binding of melatonin to its receptor 1 leads to the activation of mitogen-
activated kinase (MAPK). MT1 tentatively activates the nuclear receptor RZR/ROR 
(termed retinoid receptors) and it is suggested that the anti-oxidant effect of melatonin is 
mediated via the interaction of MT1 and RZR/ROR (Rodriguez et al., 2004). This co-
localisation with the RZR/ROR receptor modulates calcium release via 
Ca++/caldmodulin signalling (Rodriguez et al., 2004) MT2 regulates the circadian rhythm 
via the activation of guanylyl cyclase (Masana et al., 2002). 
Melatonin receptor 3 (MT3) is a putative receptor with a distinct pharmacological profile 
from MT1 and MT2. It was identified in the hamster brain that MT3 and quinone 
reductase 2 (QR2), both bind to the iodolmelatonin with the same pharmacological 
profile (Masana et al., 2002). Evidence suggests that MT3 is actually QR2 present as a 
cytosolic enzyme and is not membrane-bound. The complete identity of MT3 membrane 
binding sites with the quinone reductase 2 remains enigmatic (Dubovovich & 
Markowska, 2005; Ekmekcioglu.2006) 
Melatonin receptors are located in the vascular beds. MT1 and MT2 are detected in the 
cerebella arteries in humans. Melatonin modulates both vasoconstriction and 
vasodilation depending on which receptor mediates the response (Marillet et al., 2009, 
Masna et al., 2002). In the rat caudal artery, melatonin potentiates the adrenal nerve 
stimulation. Vasoconstriction was mediated via the reduction in cAMP phosphorylation 
of the voltage-gated potassium channels (BKCa) through MT1 predominantly present in 
the smooth muscles and regulates estrogenrelease (Marillet et al., 2009, Girgert et al., 
2009). MT1 also leads to the activation of protein kinase 1 and 2 (MEK1, MEK2). 
Furthermore, MT1 is present in the hippocampus and it is proposed to regulate blood 
flow as well as diurnal blood pressure fluctuation (Pong et al., 2002). Conversely, MT2 
is involved in the reduction of vascular tone (Pong et al., 2002). Melatonin bound to MT2 
increases blood flow to the skin and may regulate heat loss. This receptor is important 
for the adaptations required for seasonal change. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 36  
 
MT3 seems to play a role in the regulation of the immune system as well as regulating 
ocular pressure, but its exact function in the heart is unclear. MT3 prevents the 
recruitment of leukocyte adhesion molecules (Mailliet et al., 2005, Menendez-Palaez et 
al., 1993). 
4.2.1 Melatonin confers cardioprotection  
Many studies enumerate the cardioprotective effect of melatonin against ischemic 
damage and altered physiology. Tan et al, showed that Langendorff perfused hearts 
that underwent 10-minute ischemia followed by 10-minute reperfusion, had increased 
ventricular fibrillation (VF) and premature ventricular contraction (PVC) by 80% (Tan et 
al., 1993). However, melatonin treatment (1µM, 10µM, 50µM) decreased both VF and 
PVC. This was compared to the effect of vitamin C (500µM). Vitamin C was significantly 
less effective than melatonin in reducing VF and PVC. Similarly, Kaneko et al. found 
that melatonin (100µM) prior to I/R also reduced VF and improved the overall function of 
the left ventricle. Other studies with melatonin and its analogue, 5-methoxy-
carbonylation-N-acetyltryptamine (5-MCA-NAT) protected against I/R injury (Lopez et 
al., 2003, Szarszoi et al., 2001). The protective effect of melatonin ex vivo was 
corroborated with in vivo studies. All melatonin-treated rats had improved VF and 
reduced mortality rates (Lagneux et al., 2000).  
In rats, the long-term effects of melatonin were evaluated 24 hours after melatonin 
administration (2.5 or 5.0 mg/kg, ip) or after the oral supplementation of melatonin in the 
drinking water for seven days (20 or 40µg/mℓ) (Lochner et al., 2006). These results 
suggest that melatonin induces long-term protection as evidenced by the reduction of 
infarct size. The cardioprotective effect of melatonin persisted for two to four days after 
discontinuation of treatment. Chronic administration of melatonin (10mg/kg) for one 
month after mice were born modulated the expression of senescene-accelerated-prone 
mice (SAMP8) and reduced the Aβ fibres (Gutierrez et al., 2008). The oxidative stress 
was also markedly reduced and enhanced the activation of Bcl-2 (Forrest et al., 2007). 
The protective effects of melatonin can reduce I/R injury in other organs including the 
brain, liver, kidney, placenta and GIT (Forrest et al., 2007). Patients with rheumatoid 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 37  
 
arthritis treated with melatonin (10mg/day) given orally had reduced inflammatory 
cytokines (Maney et al., 1996).  
 
Figure 18: The cardioprotective properties of melatonin. SCN (suprachiasmatic nucleus), 
Mel(melatonin),SCG (superior cervical ganglion), RHT (retinohypothalamic tract) (Dominguez-Rodriguez 
et al., 2012).  
4.3 Mechanism of melatonin-induced cardioprotection 
Melatonin can scavenge free radicals directly by inhibiting their formation or alternatively 
via the upregulation of anti-oxidant enzymes, thus improving its anti-oxidant capabilities 
(Zang et al., 1998). The direct scavenging effects of melatonin are receptor-independent 
and the effects of melatonin as an antioxidative are receptor-dependent (Tan et al., 
1993).  
4.3.1 Melatonin and its other effects  
Melatonin does not possess a hydroxyl group, like other anti-oxidants such as vitamin 
E, and hinders the formation of lipid peroxidation by curtailing the initial factors that 
promote oxidation, and not via the direct breaking of the chain (Karbownik et al., 2000). 
A study comparing melatonin and vitamin E found that melatonin was twice more 
effective in scavenging free radicals (Pieri et al., 1996). Even melatonin‟s metabolite 6-
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hydroxymelatonin acts as a powerful free radical scavenger and promotes detoxification 
(Scinivasan et al., 2002). Melatonin detoxifies H202 directly and increases glutathione 
peroxidase (GPX), catalase (CAT), superoxide dismutase (SOD) and MnSoD (Reiter et 
al., 2003). Melatonin modulates Ca++ signals because of its fixation to calmodulin which 
influences adenylyl-cyclase and phosphodiesterase (Petrosillo et al., 2006, Petrosillo et 
al., 2009). Furthermore melatonin can regulate the release of Ca++ directly by acting on 
the voltage gated Ca ++ channel. Furthermore, melatonin increases the efficiency of the 
electron transport chain by lowering e-leakage from complex 4 and in turn, reduces free 
radical release and therefore, improves mitochondrial function (Chen et al., 2005, 
Okatani et al., 2003). Also, melatonin reduces the effects of reperfusion by regulating 
the production of cardiolipin and in turn regulates the opening of the mitochondrial 
permeability pore (mPTP) (Petrosillo et al., 2009). The inhibition of the mPTP promotes 
cardioprotection (Petrosillo et al., 2009). Therefore, any drug such as melatonin that 
influences the mitochondrial permeability pore may mitigate the adverse effects of acute 
myocardial infarction.  
Atherosclerosis is the abnormal development and progression of cholesterol deposits in 
the tunica intima of arteries.  
The development of the plaque involves the activation of inflammatory cytokines and 
oxidised LDL (Pieri et al., 1996). According to the oxidative modification hypothesis LDL 
becomes mildly oxidised in the arteries and leads to the recruitment of a variety of 
vascular cells. These cells activate the monocytes chemotactic protein 1 (Pieri et al., 
1996). Consequently, the LDL is recognised by the scavenger receptors on the 
macrophage. The macrophage internalises the LDL and forms a foam cell. It is not 
subject to negative feedback and thus increases the uptake of cholesterol (Okatani et 
al., 2000). LDL has direct chemotactic effects on the monocyte and promotes the 
binding of the monocyte to the endothelium walls (Kelly et al., 1997).The LDL becomes 
trapped in the sub-endothelial space because LDL inhibits regress of the arterial wall. 
This is supported by the extensive presence of LDL in the atherosclerotic lesion. Also 
LDL is oxidatively altered in vitro. Melatonin inhibits oxidised LDL in vitro in a dose-
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dependent manner (Duell et al., 1998). Other studies support these findings and 
suggest that melatonin precursors (such as L-tryptophan and serotonin) as well as the 
breakdown products (such as niacin or quinolinate) also inhibit oxidation of LDL (Duell 
et al., 1998). Melatonin reduces the total cholesterol plasma levels and decreases very 
low-density lipoproteins, (VLDL) in hypercholesterolemic rats (Kelly et al., 1997).  
4.3.2 Melatonin and other mechanisms  
Melatonin treatment lessens inflammation by reducing the oxidative stress. It targets the 
binding of leukotriene B4 (LKB4) to the endothelial cells and reduces the mobilisation of 
NFkB and in turn prevents the recruitment of ICAM, VCAM and P-selectin (Kelly et al., 
1997). Melatonin targets chronic inflammation by blocking the translocation of NFKB 
and reduces ROS formation in the cells (Li et al., 2005). Melatonin also inhibits 
cyclooxygenase (COX-2) and inducible nitric oxide sythetase (iNOS) (Deng 2006). In 
patients with rheumatoid arthritis, patients treated with melatonin (10mg/day) had 
reduced inflammatory cytokines. In elderly patients melatonin (5mg/day) reduces the 
effects of hypertension compared to placebo (Lusardi et al., 2002). 
Clinically, melatonin reduces the effects of oxidative stress in humans subjected to 
cardiopulmonary bypass surgery (Ochoa et al., 2003). Whether it is the reduction in 
melatonin that causes disease or the disease that reduces melatonin levels remain 
unclear. Moreover, melatonin given at the onset of major surgery also reduced the by-
products of lipid peroxidation in the erythrocyte membrane and in the blood (Ochoa et 
al., 2003). Hypertension is one the leading risk factor for IHD and HF (Steyn et al., 
2005). Pinealectomised rats have diminished melatonin levels and are strongly 
associated with vasoconstriction and temporary hypertension (Stewart et al., 2006). 
However, these effects were reversed with melatonin administration (Zanoboni et al., 
1967). The role of endogenous melatonin in cardioprotection is further illustrated in 
pinelectomised mice that present with a mortality rate of 63% compared to zero 
mortality in the intact mice. Interestingly, continuous exposure to light both day and 
night prevents the nocturnal increase of melatonin, suppresses circadian heart rate and 
augments blood pressure, resulting in melatonin-deficient hypertension (Rezzani et al., 
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2010, Paulis et al., 2010). SHR with left ventricular hypertrophy were treated with 
melatonin and improved cardiac function but did not alter the left ventricular relative 
weight (Zanoboni et al., 1967). Clinical studies in hypertensive patients demonstrated 
that chronic melatonin treatment (2.5 mg/day) significantly reduced blood pressure after 
three months (Scheer et al., 2004). These results strongly suggest that melatonin plays 
a major role in the regulation of hypertension. It has been shown in an experimental 
model that pharmacological concentrations of melatonin are receptor-dependent and 
are mediated via the activation of the Akt/Erk pathway (Genade et al., 2008).  
4.3.3 Melatonin is present in red wine 
Melatonin is synthesised by various plants such as rice, berries and grapes (Iriti 2009, 
Hattori et al., 1995). In 2006, Italian researchers found the presence of melatonin in 
extracts from different wine grapes including Nebbiolo, Croatina, Sangiovese, Merlot, 
Mrzemino, Cabernet Franc, Cabernet Sauvignon and Barbera (Iriti et al., 2010). 
Melatonin was found in a high concentration in red wine ranging from 50pg/mℓ to 
200pg/mℓ. Interestingly, the amount of melatonin is lower in white wine (range: 10-
50pg/mℓ) and even less in liquors (range: 5-20pg/mℓ) (Guerrero et al., 2008) (see Figure 
19).  
 
Figure 19: Melatonin concentration in varying alcoholic beverages (Guerrero et al., 2008).   
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It is likely that cultivar, agro-meteorological conditions (Iriti et al., 2010), vintage and 
wine-making procedures contribute to the difference in concentration of melatonin 
between the wines (Iriti et al., 2010). Ironically, the anti-mould fungicide 
benzothiadiazole, which wineries spray on their plants to protect the grapes, seems to 
increase the concentration of melatonin (Iriti et al., 2010). Interestingly, Guerrero et al., 
(2008) demonstrated that serum melatonin was significantly increased in humans, one 
hour after an intake of 100 mℓ of red wine. However, for unknown reasons, this article 
has been withdrawn at the request of the editor of the relevant journal.  
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B. Aims and hypothesis 
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1 Aims  
Ischemic heart disease (IHD) is a global burden and additional therapies are urgently 
required to assist in the prevention and curing of the disease. Both epidemiological 
studies and experimental studies have shown that the regular moderate consumption of 
red wine confers cardioprotection against IHD. Delineating the cardioprotective 
components present in wine that contribute to this cardioprotective effect may lead to 
the development of novel therapies against IHD. The presence of melatonin, a biogenic 
amine present in foods, but also produced naturally in the body to regulate sleep, has 
recently been identified in red wine (Guerrero et al., 2008). Melatonin protects against 
I/R injury but whether it contributes to the cardioprotective effect of red wine remains 
unclear (see Figure 20).  
 
We therefore hypothesised that the presence of melatonin in red wine contributes to the 
cardioprotective effect of the regular moderate consumption of red wine against IHD. 
We further suggest that this cardioprotective effect may be mediated via the activation 
of the SAFE pathway that involves the modulation of TNFα and STAT3.  
To investigate our hypothesis the following objectives were pursued 
1.1 Objectives 
 
1) Using an in vitro model of I/R our objective is to demonstrate that the acute 
treatment with melatonin, at concentration found in red wine, can confer 
cardioprotection. We further propose that this cardioprotective effect is mediated 
via the activation of the SAFE pathway (Chapter 1).  
2) Using both an ex vivo and an in vivo model of I/R we aim to demonstrate that the 
chronic and moderate consumption of red wine or melatonin protect against I/R 
injury via the activation of the SAFE pathway. Furthermore, melatonin receptor 
inhibitors were used to explore the exact role of melatonin in red wine-induced 
cardioprotection (Chapter 2).  
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3) Using an in vivo mouse model of ischemic heart failure we aimed to demonstrate 
that the cardioprotective effect of a low and chronic treatment with melatonin can 
be extended to ischemic heart failure. (Chapter 3). 
 
Melatonin
Resveratrol
Cell Survival against ischemia/reperfusion injury 
and heart failure
?
 
 
Figure 20: Hypothetical mechanism for red wine-induced cardioprotection mediated via the activation of 
the SAFE pathway. 
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C. MATERIALS AND METHODS 
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1 Animals used  
Experiments were conducted on either male Wistar rats weighing 230-300g or mice 
ranging from 12-14 weeks, and were performed in accordance with the Guide for Care 
and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH 
publication No. 85(23), revised 1996). All procedures were approved by the Animal 
Research Review Committee of the University of Cape Town (applications; 011/026 
“Cardioprotection with red wine and its active components in an in vivo mouse model of 
heart attack/HF” 008/026 entitled “Delineation of mechanisms for wine-induced 
cardioprotection”, 007/012 “Delineation of resveratrol-induced cardioprotection” 005/016 
“The cardioprotective effect of alcohol-free wine”  
 
2. In vitro mouse model of I/R injury 
2.1 Types of mice  
Homozygous TNF deficient mice (TNF receptor 2 -/-) , and their respective wild-type 
littermate control Black 6 x 129 (TNF-WT) were donated by Dr Muazzam and Professor 
Bernhard Ryffel from the Department of Immunology and Infectious Diseases, 
University of Cape Town.   
 
Takeda et al. showed that whole-body STAT3 knockout (KO) mice resulted in the death 
of the embryo between 6.5- 7.5 days of gestation (Takeda et al., 1997). Thus STAT3 is 
crucial for the early development of the embryo. Consequently, the STAT3 knockout 
(KO) mice were created as cardiomyocyte-specific, deficient mice achieved by using the 
Cre-Lox P system of conditional gene ablation.  
Cardiomyocyte-specific STAT3 deficient (STAT 3 -/-) mice were from a C57 Black 6 
background created at the Hatter Institute by crossing homozygous floxed STAT3 mice 
with a heterozygous myosin light chain 2 ventricle (MLC2V)-driven Cre-recombinase 
mice, as described by Smith et al., 2002.   
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2.2 The Langendorff perfusion isolated mouse heart model 
The Langendorff perfusion system is a retrograde perfusion system, with the heart 
cannulated at the aorta and maintained at constant pressure. It was first discovered in 
1895, by the German physiologist Sir Oskar Langendorff who isolated and perfused 
mammalian heart preparations (Langendorff et al., 1895). It is widely adopted in cardiac 
physiology for the examination of contractile strength, heart rate and other vascular 
effects. The simplicity of the model has led to its frequent use in both basic and pre-
clinical drug research and experiments can be conducted on both rats and mice.  
 
2.3 Preparation of the Langendorff system  
The system was flushed several times with boiling water to remove any bacteria and 
endotoxins. Krebs Henseleit Buffer (KHB) was prepared daily because if kept for a 
longer period of time the calcium would precipitate and cause a blockage in the 
perfusion system. The KHB was made as described in the table 1, in mM to make 5L of 
water. The composition of KHB was set to mimic body plasma as much as possible to 
keep the heart viable outside the body. The different compounds were added to 4L of 
distilled water, with calcium and glucose added after the other compounds had been 
oxygenated with (95%O2 and 5% CO2). Thereafter the pH of the KHB was maintained at 
7.4 and the solution made up to a final volume of 5L with distilled water. The KHB was 
further oxygenated for 20 minutes before use. The Powerlab Data Acquisitions 
software™ (ADInstruments™) was used to measure functional parameters which were 
calibrated daily with a sphygmomanometer for accurate readings.  
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Table 1: The composition of KHB for mouse perfusion.  
Krebs-Henseleit perfusion buffer 
mM Grams (g)/ℓ 
118.0 NaCl 34.5 
24.0 NaHCO3 10.1 
4.0 KCl 1.5 
1.0 NaH2PO4 0.7 
1.2 MgCl2 1.2 
2.5 CaCl 1.85 
 0.5 EDTA 0.95 
 10.0 Glucose  9.0 
 
2.4 Mounting of the heart on the system 
Adult male TNFα -/- , TNF R2 -/- and cardiomyocyte specific STAT3 -/- mice and their 
wild-type littermates were anesthetised with 60 mg/kg intraperitoneal sodium 
pentobarbitone mixed with 20 international units (I.U.) of heparin. To determine 
adequate anaesthesia prior to the opening of the chest, the pedal test was implemented 
whereby the complete lack of a reflex was an indicator for adequate anaesthesia. The 
sternum and the costal cartilage were excised for the complete view of the 
mediastinum. The mouse hearts were rapidly removed from the chest cavity and placed 
in cold KHB buffer, to reduce enzymatic activity. The heart was cannulated via the 
aorta, and perfused retrogradely using the Langendorff perfusion system at a constant 
pressure (100 cm H20), at 37ºC by inserting a fine thermo-coupled wire monitored on a 
digitron 2600T (Torquay, UK).  
 
The developed tension was assessed, with a weight that created a force of 2g to work 
against, by utilising a rigid lightweight lexan coupling rod connected to a force 
placement transducer (Grass FT03C, MA, USA) (see Figure 21). A 4.0 suture attached 
to a 20mm atraumatic needle was threaded 1 mm from the tip of the apex of the heart 
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and fastened firmly onto the coupling rod. All the hearts were equilibrated to pull at 2g 
weight and were paced at 560bpm. Tension output was recorded on the Powerlab chart 
recorder (ADI Instruments, Australia) as described by Smith et al., 2002.  The isolated 
mouse hearts were left to calibrate for 20 minutes prior to 35 minutes of global ischemia 
(total cessation of perfusate by closing the three-way stopcock to prevent flow from the 
aortic cannula; in addition, KHB was added into the jacket to maintain temperature of 
37ºC at all times) followed by 45 minutes reperfusion (Smith et al., 2002).  Cardiac 
parameters were monitored throughout the experiments and included heart rate (HR), 
coronary flow (CF) and developed force (DF).  
 
2.5 Exclusion criteria 
Mice that did not comply with the following criteria were removed from the study; (1) 
Coronary flow must be a minimum of 1.5mℓ/minute and a maximum of 5.0mℓ/minute,(2) 
Heart rate should be a minimum of 460–600 beats/min, (3) Developed force must be 
greater than or equal to 4mg. An exclusion criterion provides a baseline for consistency 
and standardisation of each heart mounted onto the system. At the end of the 
experiments, the hearts were removed and 1mℓ of 1,2,3 triphenyleterazolium chloride 
(TTC, 1% phosphate buffer, ph 7.4) was infused into the hearts through the stopcock. 
The hearts were frozen at -4ºC and kept for a maximum of one week before infarct size 
analysis.  
 
 
Retrograde perfusion
Clip attached to pacer
Temperature probe
Tension lever  
Figure 21: Mouse heart mounted on the Langendorff apparatus. The heart is retrogradely perfused via the 
aorta.  
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3. Isolated rat heart model 
Laboratory rats are derived from the wild Norway rat Rattus Norvegicus. Rats were first 
domesticated for laboratory use in 1828 and utilised for research (Farkas et al., 2008). 
Wistar rats are mutant albino rats belonging to the same strain. Wistars are currently the 
most popular rat strain used for laboratory research and are characterised by their wide 
heads, long ears and long tail. They are easily bred and commercially available in large 
quantities, small in size with minimal maintenance cost and are well characterised 
anatomically, physiologically and genetically and therefore perfect for research (Farkas 
et al., 2008). 
3.1 Preparation of Langendorff perfusion system 
The hearts were mounted onto the perfusion system and perfused retrogradely through 
the ascending aorta, which forces the aortic valve closed and shunts the blood toward 
the coronary ostia into the coronary arteries. The perfusion system must remain at a 
constant pressure (100 cm H20), at 37ºC, with KHB equilibrated with 02/CO2 95:5%. To 
prepare the KHB different compounds were added to 4L of distilled water, with calcium 
and glucose added after the other compounds had been bubbled with (95%O2 and 5% 
CO2,), see table 2.Thereafter the ph of the KHB was maintained at pH of 7.4 and the 
solution made up to 5L with distilled water. The composition of the rat KHB was slightly 
different to the mouse system. These conditions are set to mimic bodily function as 
much as possible to keep the heart viable outside the body and are similar to the mouse 
model as described in this section.   
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Table 2: The composition of the KHB for rat perfusion.  
 
KHB perfusion buffer 
mM Grams (g)/5L 
118.0 NaCl 34.63 
25.2 NaHCO3 10.5 
4.7 KCl 1.77 
1.2 MgSO4.7H2O 1.47 
1.2 KH2PO4 0.8 
1.2 CaCl.2H20 1.0 
 11.0 Glucose  10.99 
 
Before mounting the heart the system was flushed with boiled distilled water daily to 
remove any bacteria and endotoxins from the system as mentioned in the mouse 
model. A fresh batch of KHB was made daily, as keeping it for more than a day leads to 
the precipitation of calcium or glucose, which is detrimental to the heart. After the KHB 
was made to a final volume of 5L it was further oxygenated for 20 minutes before use, 
as mentioned in the mouse model. The Powerlab Data Acquisitions Software™ 
(ADInstruments™) was used to measure functional parameters which were calibrated 
daily with a sphygmomanometer for accurate readings.  
3.2 Mounting of the rat heart onto the Langendorff perfusion system  
Rats were anaesthetised with a 60 mg/kg intraperitoneal injection of sodium 
pentobarbitone and mixed with 200 IU heparin. The animals were placed in a quiet 
room and left for 15 minutes to acclimatise and before anaesthesia for stress reduction. 
Stress causes the release of catecholamines and other circulatory factors which can 
affect the functioning of the heart, which can affect experimental outcome. The depth of 
anaesthesia was assessed with the pedal reflex, whereby the paw of the animal was 
pinched and its perception of pain was observed.  
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Thoracotomy was performed when the rat was deemed unconscious. A forward incision 
of the skin at the xyphoid-sternum (sternotomy) was delicately performed. The incision 
continued along the proximal ends of the left and right costal margins. The thoracic 
cavity was opened by and the pericardium surrounding the heart removed thereby, 
exposing the beating heart in the chest cavity. The heart was firmly cradled and hosted 
between the thumb and the index finger and removed with one quick precise incision 
without inflicting damage to the aorta. The isolated heart was immediately placed into 
ice-cold KHB to arrest the heart. 
The heart was mounted onto the cannula with two pairs of forceps stretching the aorta 
on either side to ensure a snug fit onto the cannula while perfusate dripped from the 
cannula to enable a fluid-fluid connection. The heart was temporarily secured with a 
bulldog clamp in order to keep it in place. Thereafter, a thin suture tied around the aorta 
connected to the cannula was used to securely fasten the heart, see figure 22. The 
pulmonary artery was punctured to release the pressure build-up in the coronary ostia. 
Subsequently, the left ventricle was exposed with a small excision of fat deposits 
surrounding the left atria, to enable the balloon insertion into the left ventricle for 
hemodynamic measurements. The intraventricular balloon attached to a catheter filled 
with distilled water was connected to a pressure transducer. Inside the left ventricle, the 
balloon was inflated and filled with distilled water, thus creating a closed system to 
measure the pressure experienced by the left ventricle, see figure 23. 
 
 
 
Figure 22: Rat heart mounted on the Langendorff perfusion apparatus.  
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The left ventricular end diastolic pressure was adjusted between 4 and 12mmHg and 
the hemodynamic parameters were assessed as follows. 
Cardiac parameters were monitored throughout the experiments and included heart rate 
(HR), left ventricular developed pressure (LVDP: difference between left ventricular end 
systolic pressure (LVESP), end diastolic pressure (LVEDP) and the coronary flow (CF). 
Functional recovery was expressed as LVDP X HR at a specific time point compared to 
the stabilisation 
 
Pressure 
Transducer 
3-way 
cock 
Balloon 
Catheter 
Water Syringe  
Chart 
recorder Needle 
Figure 23: Schematic representation of the balloon catheter. (AD Instruments, London). 
 
3.3  Exclusion criteria 
Rats that did not comply with the following criteria were removed from the study:( 1) Left 
ventricular pressure must be higher than 80mmHg; (2) Coronary flow must be a 
minimum of 8mℓ/minute and a maximum of 16mℓ/minute; (3) Heart rate should be a 
minimum of 240 beats/minute.  
 
3.4 Ischemia reperfusion models  
Ischemia reperfusion models were ideal to study cardiac physiology for the examination 
of contractile strength, heart rate, coronary flow and other vascular effects. The model 
was used to test drugs of interest in protecting against I/R. 
3.4.1 Regional Ischemia 
In regional ischemia, a 3/0 silk suture was placed around the left ascending coronary 
artery to form a snare to simulate ischemia. Drugs of interest were administered prior to 
the ischemic insult and were directly administered to the heart through a side pump 
attached to the system.  
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Thereafter, the snare was tightened and blocked off, the flow of buffer to that specific 
region of the heart, thus ischemia was induced for 30 minutes. KHB was returned and 
the heart was reperfused for 120 minutes. Clinically, this setting mimics the blockade of 
an artery in the heart which eventually leads to myocardial infarction. At the end of the 
protocol the snare was tightened and 1% Evans blue was perfused through the three-
way stopcock into the non-ischemic areas of the heart. The Evans blue, is a 
monochromatic stain, blue in colour and used to delineate the dead cells; in the 
ischemic area, the non-ischemic area or the area at risk.  Thereafter, the heart was 
removed and stored at -4ºC for infarct size analysis.  
3.4.2 Global ischemia 
Hearts were equilibrated and subjected to 30 minutes global ischemia followed by 60 
minutes of reperfusion. Global ischemia was used for all the chronic studies and was 
achieved by the complete cessation of perfusate together with additional KHB within the 
jacket to maintain temperature at 37ºC. In this setting the drugs administered to salvage 
the heart were given chronically for 14 days, prior to the global ischemia. At the end of 
reperfusion, hearts were removed and stored at -4 ºC for infarct size analysis. Global 
ischemia mimics the complete cessation of flow of blood as attained during coronary 
bypass or heart transplants in the clinical setting. 
All pharmacological agents were purchased from Sigma Chemicals Company (St Louis, 
MO, USA), if not stated otherwise. Luzindole and prazosin, a melatonin inhibitor was 
obtained from Tocris bioscience (London, England).  
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Temperature maintained at 37°Isolated rat heart
Male Wistar rat
Hemodynamic 
parameters
 
Figure 24: Isolated rat hearts were mounted onto the Langendorff system and hemodynamic parameters 
were assessed.  
4. In vivo mouse model of  I/R injury 
Male mice (12-14 weeks) were anaesthetised with a combination of ketamine 
(0.06mg/mℓ) and xylazine (2mg/mℓ); the final concentration of both was 0.01mg/mℓ and 
the body temperature was maintained at 37 degrees (Lim et al., 2007). Non-recovery 
procedures used ketamine/xylazine as the anaesthetic of choice based on the following 
criteria: (1) rapid induction for a relatively long duration (± 90 minutes); (2) excellent 
muscle relaxation; (3) a dissociative anaesthetic; (4) disruption of pain transmission and 
suppression of spinal cord activity with some action on opioid receptors (Green et al., 
1981). The ketamine/xylazine was used for acute experiments because it has a less 
pronounced cardioprotective effect (Roth et al., 2002).  
However, for recovery animals (permanent ligations for ischemic HF), 4% isoflurane, 
prior to intubation this was reduced after intubation to 2% isoflurane mixed with oxygen 
were administered based on the following criteria: (1) the cardiopulmonary depression is 
not as extensive as gases that require inhalation; (2) reduced sensitisation of heart, by a 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 56  
 
reduction in the catecholamines; (3) reduced respiratory depression; (4) rapid induction 
and recovery (Green et al., 1981). It has been suggested by that isoflurane used in 
long-term studies has a less pronounced cardioprotective effect because there is 
sufficient time for drug metabolism and excretion (Flecknell, 1996).  
After the administration of anaesthesia (either xylazine/ketamine or isoflurane) the pedal 
reflex test was performed to ensure deep sleep. Thereafter, a tracheotomy was 
performed. The mice were intubated for artificial respiration at 120 strokes/minute and 
220µl stroke volume using a minivent (Kent Scientific; Torrington CT). A left anterior 
thoracotomy was performed in the third intercostal space (retractors were used for clear 
visualisation of the heart) and the pericardium was removed. The left ascending 
coronary artery was ligated with ligature, 8.0 ethilon, nylon suture black filament, 2mm 
below the tip of the left auricle. A snare was created with a small piece of rubber tubing 
to create the ischemic insult for 30 minutes and then released and reperfused for 120 
minutes. The experiments were terminal and the mice were sacrificed. At the end of the 
protocol, 200-500µl of Evans blue of which was injected directly into the left ventricle of 
the heart until the extremities of the mouse changed colour. The heart was squeezed 
and rinsed vigorously in saline to remove blood clots. Thereafter, the hearts were stored 
at -4ºC and sectioned a week later. 
 
For the long-term studies, IHF was assessed; the left ascending coronary artery was 
permanently ligated (Salto-Tellez et al., 2004). The ribs were sutured together with 5.0 
prolene blue monofilament polyprolene suture and the chest closed. Thereafter, the 
isoflurane flow was ceased and the mice were ventilated on oxygen only, until fully 
conscious. The mice were kept and assessed daily for 28 days. 
Buprenorphine (0.05mg/kg, ip) was administered as an analgesic with a single dose 
given before surgery and administered every 12 hours post operation for 5 days 
(Adamson et al., 2010). Buroprenorphine has an antinociceptive effect and is 
considered a multimodal analgesic due to its action on the opioid receptors.  
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The maximum efficacy is between 3-6 hours and has a bioavailability of 24-72 hours 
after initial administration (Adamson et al., 2010). Prior to the ligation and before the 
termination hemodynamic function was assessed with an echocardiogram. 
5. Infarct size assessment 
At the end of the experiments, the hearts that underwent global ischemia were removed 
from the perfusion system and stained with either triphenyltetrazolium chloride (TTC, 
1% in phosphate buffer, ph7.4). TTC reacts with ubiquinone reductase (NADPH) in live 
tissue and stains the cells with a brick red colour, on the contrary the infarcted tissue 
lacks NADPH and remains white. The hearts were frozen overnight and sectioned 
perpendicular to the apex, into 1mm slices and placed into 10% formalin for 12 hours.  
Thereafter, the sectioned hearts were kept for one week. The hearts were stained with 
warm TTC (1%) solution poured into petri dishes. The frozen hearts were slightly 
defrosted and sectioned, once all the residual water had been removed the hearts were 
placed into the petri dishes with TTC solution and were maintained for 15-20 minutes at 
37ºC. Thereafter, the TTC solution was decanted and 10% formalin was added for 12 
hours at room temperature.  
The hearts, whether stained with TTC alone or Evans blue, were mounted in between 
two glass plates at a distance of 0.5mm for compaction for clear digital scanning. Infarct 
size was quantified with computerised planimetry (Planimetry+, Boreal software, 
Norway). 
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Figure 25: A graphical representation of Evans blue and TTC staining for infarct size. 
 
6. Western Blotting 
Rat hearts were harvested and perfused as previously described. The hearts were 
subjected to different acute treatments (control, melatonin and resveratrol) and freeze-
clamped prior to the ischemic insult (after removal of atria). An additional group that was 
chronically pre-treated with red wine was collected at 15 minute into reperfusion, for 
later Western Blot analysis to explore the levels of total and phosphorylated STAT-3 on 
the tyrosine residue in the heart. 
6.1 Nuclear and cytosolic protein extraction 
Frozen tissue was wrapped in foil and pulverized with a hammer and liquid nitrogen. 
The powdered tissue (200mg) were homogenized by Polytron, at setting 4, with 900μl 
lysis buffer (20mM HEPES, 2.5mM MgCL2, 100μM EDTA, 20mM β- glycerophosphate, 
0.05% Triton x-100 (cytosolic extract), 1% Triton x-100(nuclear extract),  dithiothereitol 
(DTT), phenylmethylsulfonyl fluoride (PMSF) and NaCl and centrifuged at 10000g for 5 
minutes at 4°C with the lysis buffer. The supernatant (crude cytosolic extract) was 
removed and corresponded to the crude cytosolic extract. Thereafter, 500μl, 
resuspension buffer, was added to the remaining pellet and homogenized and 
centrifuged at 15000g for 30 minutes, see table 3. The supernatant was removed and 
corresponded to the crude nuclear extract. 
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Table 3: Compounds required to make up lysis buffer and resuspension for the extraction process. 
Lysis buffer Resuspension buffer 
Solution ( 30mℓ) µl     Final 
Concentration 
Solution ( 10mℓ)                µl Final 
Concentration 
1M Hepes, ph 7.9 600 20mM 1M Hepes, ph 7.9 200 20mM 
2M MgCl2 37.5 2.5mM 2M MgCl2 12.5 2.5mM 
500mM EDTA 6 100µM 500mM EDTA 2 100µM 
100mM 
glycerolphosphate 
6000 20mM 100mM 
glycerolphosphate 
2000 20mM 
TritonX-10 
0(100%) 
15 0.5% TritonX-10 
0(100%) 
100 1.0% 
100 mM DTT 1500 500µM 100 mM DTT 1500 500µM 
100mM  NaV04 30 100µM 100mM  NaV04 10 100µM 
EDTA  protease 
inhibitor (tablet) 
1200 - EDTA protease 
inhibitor (tablet) 
400 - 
100 mM PMSF 300 1mM 100 mM PMSF 100 1mM 
5M NaCl 450 75mM 5M NaCl 150 75mM 
dH20 19862 - dH20 6526 - 
 
 
6.2 Protein quantification 
The Lowry Assay was used to quantify the concentration of proteins after the extraction 
process (Lowry et al.,1951). Bovine Serum Albumin (BSA) standard curve ranged from 
a concentration of 5-200mg/ℓ and the absorbance was measured at 250 nm; see details 
below. The aliquots of 5µl of nuclear and cytosolic of protein was added to 995 µl of 
distilled water. A standard curve was prepared using bovine serum albumin (Sigma, 
Germany) diluted to provide a concentration ranging from 10-200µg/ml. CTC reagent 
(colour reactive agent): solution a (Na2C03 in 20g/100mℓ in double distilled water, 
ddH20) was added to solution b (0.2g CuS04.5 H20 + 0.4 g K2 tartate in 100mℓ ddH20) 
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and constantly stirred to prevent precipitation. The 10% SDS was made by diluting 20% 
SDS solution (w/v).The 0.4g of sodium hydroxide (NaOH) was added to 200mℓ ddH20.  
Equal volumes of all three reagents were mixed immediately and prepared before use. 
All the samples were quantified in duplication. 5µl of protein of aliquot either nuclear or 
cytosolic origin was added to 995µl of sterile distilled water (1:200 dilution). 1mℓ of CTC 
reagent was added to each tube and mixed immediately and incubated at room 
temperature for 10 minutes. 500µl of folins reagent (1:5 dilution, Merck Germany) was 
added immediately. Folins agent has a short half-life of 8 seconds and must be used 
quickly, so the samples were incubated for 30 minutes. Thereafter, the optical density 
was measured at 750nm on Varian 130 dual beam spectrophotometer (Peterson 1977). 
Bovine serum albumin protein (BSA, Sigma Germany) was used for the standard curve 
and diluted to a concentration ranging from 10-200µg/mℓ and was assayed in the same 
manner as samples. 
6.3 Sulphate dodecyl sulphate  polyacrylamide gel electrophoresis (SDS 
PAGE) of extracted proteins 
Lysates, 100µg, were diluted in Laemli sample buffer and boiled for 5 minutes. 100μg of 
proteins were separated on a 10% sodium dodecyl sulphate (SDS PAGE) gel, using 
standard Bio-Rad Mini-PROTEAN ІІ System for two hours at 120 volts before being 
transferred to nitrocellulose membrane (Amersham Bioscience Hybond PRPN 303F) 
overnight. 
 
6.4 Immuno-blotting and detection 
The membranes were stained with a Ponceau Red stain (Ponceau‟s solution sigma, 
USA P7170) to check for equal loading. Membranes were blocked with 5% milk in Tris 
buffered saline (TBS-Tween) (0.1% Tween) for 3 hours. The membranes were probed 
with primary antibodies phospho-STAT3 (overnight) and total-STAT3 (2 hour) or β-actin, 
overnight at 4°C. 
The primary antibody (total STAT (H-190) sc-7179 Santa Cruz Biotechnology rabbit 
polyclonal, phospho-STAT3 (Tyr 705) sc-7993 Santa Cruz Biotechnology goat 
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polyclonal, was washed off with TBS -T (0.1% Tween), three times for 5 minutes. The 
membranes were probed with the secondary antibody (Biotechnology, Donkey anti-
rabbit IgG-HRP sc-2313 Santa Cruz Biotechnology, USA) for 1 hour. Detection of 
immune reagent bands were accomplished with enhanced chemiluminescence (ECL). 
The protein bands were normalised to Ponceau and β-actin 
The total-STAT3 antibody was prepared by adding, STAT3 antibody rabbit polyclonal 
IgG 1:4000 in 5% (w/v) fat free milk. The secondary antibody was left on the membrane 
for 2 hours at room temperature (anti-rabbit) 1:3000 in 5% (w/v) fat free milk. The 
primary antibody for phosphorylated STAT3 is a phosphoplus STAT3 (Tyr 705) rabbit 
polyclonal IgG 1:1000 in TBST. The secondary antibody is left after the primary 
antibody and left for 2 hours at room temperature. All of the antibodies were purchased 
from Cell signalling, USA.  
After the tSTAT3 and pSTAT3 were complete the emission of light was based on the 
interaction between the Luminol and the horseradish peroxides (HRP) conjugated to the 
secondary antibody for qualitative or semi-quantitative analysis. Relative densitometry 
was determined with use of a computerised software package, UVIBAND.  
7. Mouse echocardiography 
A transthoracic echocardiograph, using the GE Vivid E machine, is well established as a 
non invasive diagnostic procedure. It is used to assess cardiac morphology and 
performance. An ultrasound is a beam that is radiated, reflected and refracted by a 
small object. It travels poorly through air and dense substances, including lung and 
bone, thus a medium for transduction of the signal is required for its propagation. The 
intensity of the signal is directly associated with the acoustic impedances (density) of 
the medium. Reflection is also related to the thickness of the target, the angle of 
incidence of the beam penetrating the heart and the probe. The beam must be focused 
on a specific area. The beam width and frequency influence the resolution of the image 
obtained. Resolution is the ability to separate two targets as one distinct echo, to the 
extent that the systems gain button on the echo machine influences beam width and is 
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directly associated with the resolution of the image. Several factors must be considered 
for accurate ultrasound imaging: a high frequency transducer (GE i12L-RS linear array 
probe and it has a frequency range of 5.0 to 13.0 MHz), accurate positioning of the 
probe at midpapillary level, and the appropriate use of the gain controls are critical in 
obtaining a clear image (Hoit B. 2006) . 
There are two different echo modalities for capturing an image, M mode and 2 
dimensional modes (2D). The M mode, details the motion and structure along the 
ultrasound beam. Stationary structures generate horizontal lines. The distance from the 
top to bottom of the image indicates the depth and movement (Gardin et al.,1995). The 
2D mode is a cross section of the image at different positions and usually used for the 
delineation of anatomical structures for quantifying the volumes in the chambers (Kumar 
and Clarke, 2005).Therefore, mouse echocardiography has become an essential non-
invasive tool for experimental cardiovascular biology by providing a conceptual 
framework that transparently translates from the mouse to the human.  
7.1 Procedure for mouse echocardiography 
Transthoracic echocardiographies are performed in unconscious mice. The mice inhale 
2% isoflurane mixed with oxygen delivered via a nose cone. The heart rate is usually 
maintained between 250-400 beats/minute. The chest hairs are removed by shaving, 
the mice are placed onto a heating pad and maintained at 37ºC. Thereafter, the limbs of 
the mice are securely tape down. All mice are imaged in the left lateral decubitus 
position. Initially, 2D images are taken for the anatomical location of the heart to ensure 
that all the readings are taken at a mid papillary level. This is done in the parasternal 
short axis view and projected in the M mode for assessment of wall motion and wall 
thickness.  In the M mode the cursor must be placed perpendicular to the left ventricular 
septum and left posterior wall. Upon completion the isoflurane was ceased and only 
oxygen administered for recovery.  
7.2 Echocardiographic assessment of cardiac parameters in the mouse 
Left ventricular systolic dysfunction is perceived to be a hallmark for cardiac disease. 
Ejection fraction (EF) and fractional shortening (FS) are indicators of wall function in the 
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absence of abnormalities. These readings are normally taken in M mode by comparing 
the end diastolic dimensions and the end systolic dimensions. Therefore, FS is defined 
as the percentage reduction in cavity size. This is an easy method of assessment for FS 
but presents with inaccuracy for measuring EF because it does not take into account 
reduced regional function of either the mid or apical myocardium which may be due to 
infarction. Thus the EF is a mere estimation of the left ventricular volumes from systole 
to diastole and is derived from planimetered measurements. In mice the cavity of 
obliteration is 90%, which is far greater than in humans and is rarely used for 
assessment (Sahn De Maria., 1978). Other measurements for assessing wall thickness 
are intraventricular septum (IVSs) and the posterior wall (LVPw). The end diastolic 
measurements are IVSd, LVPwd and the left ventricular internal dimensions (LVIDd) are 
all assessed. FS is calculated as [(LVIDd-LVIDs)/ LVIDd] x 100%. All the left ventricular 
measurements are averaged from leading edge to leading edge. Also the heart rate was 
tracked with a minimum of 3-5 consecutive beats required for measurements.  
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2D mode for location of the heart
M mode for determination of left ventricular function
 
Figure 26: A graphical representation of the echocardiographic measurements in the left ventricle in a 
mouse heart. IVS (intraventricular septum), LVID (left ventricular internal diameter), LVPW (left ventricular 
posterior wall thickness) 2D (2 dimensional), M mode (measurement mode, 1 dimensional) (Rottman et 
al., 2007). 
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D. Chapter 1: Acute administration of 
melatonin or resveratrol protect via the 
activation of the SAFE pathway 
 
Part of this work was previously published in Lamont et al., Is red wine a SAFE sip away from 
cardioprotection? Mechanisms involved in resveratrol and melatonin-induced cardioprotection. 
2011.J of Pineal Research.50:374-380.  
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1. Introduction 
Regular and moderate consumption of wine reduces the risk of cardiovascular disease 
(St Leger 1979, Alexy et al., 2009). The red wine hypothesis proposes that red wine is 
superior to white wine in conferring cardiovascular benefits (Opie & Lecour, 2007). 
Resveratrol, a polyphenol predominantly present in red wine, raises a strong argument 
for the benefits of red wine thus supporting the red wine hypothesis. Resveratrol in red 
wine varies from 0.5 to 13.5mg/ℓ and confers anti-ischemic effects via nuclear 
mechanisms involving anti-oxidant properties as well as via the activation of prosurvival 
pathways, such as the PI3-kinase/Akt pathway (Dudley et al., 2009).  
Interestingly, another component present in red wine that has recently been discovered 
is melatonin. It is more prominent in red wine as compared to white wine and other 
liquors and therefore, favourably supports the red wine hypothesis. Melatonin is a 
natural compound well known to regulate the circadian rhythm in mammalians; it is also 
synthesized in various plants and is often used in the treatment for jet lag or insomnia 
(Cajochen et al., 2003). Melatonin concentration in red wine varies from 50 to 200ng/ℓ 
(Guerrero et al., 2008). After the consumption of 100mℓ of red wine the melatonin levels 
in patients are significantly increased in the blood plasma (Guerrero et al., 2008). 
Melatonin is a powerful anti-oxidant and is 60 times more potent than fat soluble vitamin 
E (Tan DX, 1993). Furthermore, experimental data suggest that higher concentrations 
of melatonin (40µg/ℓ) administered acutely to a rat heart on a working heart model 
confers anti-ischemic effects (Lochner et al., 2006). However, its mechanisms of 
cardioprotection still remain poorly understood. 
Recently, a novel intrinsic prosurvival pathway was discovered to protect against IR 
injury and was termed the survivor activating factor enhancement (SAFE) pathway. The 
pathway involves the activation of the innate immune system, TNFα and the 
downstream activation of STAT3. However, it is unknown whether resveratrol and 
melatonin (components predominately found in red wine) protect via the activation of 
this powerful pathway (see Figure 27). 
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We hypothesised that melatonin (75ng/ℓ) or resveratrol (10uM=2.3mg/ℓ) administered 
acutely, at similar concentrations to that found in red wine, can protect against 
ischemia-reperfusion injury in an isolated rat heart model. Genetically modified animals 
were used (TNF receptor 2 deficient mice or STAT3 deficient mice) to demonstrate that 
the acute administration of both melatonin and resveratrol, as present in red wine, can 
protect via the activation of the SAFE pathway (see figure 27). 
C ll Survival against 
Ischemia/Reperfusion injury
Melatonin Resveratrol
?
 
Figure 27: Schematic hypothesis. That melatonin and resveratrol given at low concentration protect 
against I/R injury and to determine whether this effect is mediated via the activation of the SAFE pathway. 
SAFE (Survivor Activation Factor Enhancement), JAK (Janus Kinase), STAT3 (Signal Transducer and 
Activator of Transcription). 
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2. Methods 
2.1 Animals 
All the experiments conducted on male rats (230-300g) or mice (12-14 weeks) were 
performed in accordance with the Guide for Care and Use of Laboratory Animals 
published by the U.S. National Institutes of Health (NIH publication No. 85(23), revised 
1996). All procedures were approved by the Animal Research Ethic Committee (UCT), 
009/026 “Delineating the cardioprotective effects of red wine.” 
2.2  Experimental model 
 Wistar rats (230-300g) were anaesthetised with 60mg/kg intraperitoneal sodium 
pentobarbitone and were given an intravenous injection of 200IU heparin. The hearts 
were removed from chest cavity rapidly and perfused retrogradely, using the 
Langendorff perfusion technique as previously described in the methods section.  
2.3 Isolated rat heart perfusion protocol 
The perfusion protocol is shown in Figure 28. All rat hearts were stabilised for 30 
minutes and subjected to a standard 30 minute regional ischemia (RI) with a 3/0 silk 
suture that was placed around the left coronary artery to form a snare. After the 
occlusion, the heart was reperfused for 120 minutes. Either, melatonin (75ng/ℓ) or 
resveratrol (2.3mg/ℓ), were perfused for 15 minutes followed by 10 minutes wash-out 
period prior to the regional ischemia. Additional groups were perfused with AG490 (100 
nM), an inhibitor of the JAK/STAT-3 pathway that was administered on its own or dually 
with either melatonin or resveratrol. AG490 was perfused for three minutes on its own 
followed by a 15 minute co-administration with melatonin or resveratrol, followed by a 
further five minutes of AG490 alone (see Figure 29). 
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Figure 28: Schematic representation of experimental protocol. Rat hearts were subjected to 30 minutes 
stabilisation followed by 30 minutes of regional ischemia and 120 minutes reperfusion. Prior to the 
ischemic insult melatonin (75ng/ℓ) or resveratrol (2.3mg/ℓ) was administered for 15 minutes either with or 
without AG490. 
2.3.1 Isolated TNF R2-/- and STAT-3 -/-  knockout  heart protocol 
Control
35 min GI 40min R
10
40min R15
’
D
wo’
20 min S 35 min GI
20 min S
Drug (D) 
(Melatonin/ resveratrol)
 
Figure 29: Schematic representation of experimental protocol in isolated heart model. Mouse hearts were 
subjected to 20 minutes stabilisation followed by 35minutes global ischemia and 45 minutes reperfusion. 
Prior to the ischemic insult, melatonin or resveratrol were administered for 15 minutes followed by a 
10min wash-out. S (stabilisation), min (minutes), GI (global ischemia, R(reperfusion). D(drug), 10‟wo (10 
minutes wash-out). 
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TNF receptor-2-deficient mice (TNFR2-/-) and their littermate controls (TNF-WT), 
cardiomyocyte-specific STAT-3-deficient mice (STAT-3-/-) and their littermate controls 
were used, as previously described. All mice were (12–16 weeks of age) anaesthetised 
(sodium pentobarbitone, 60mg/kg i.p.) and mounted on a Langendorff perfusion system. 
After a 30 minutes equilibration, the hearts underwent 35 minutes of global ischemia 
followed by 45 minutes of reperfusion (see Figure 29). Hearts were pretreated with 
either 75ng/ℓ melatonin or 2.3mg/ℓ resveratrol for 15 minutes followed by a 10 minutes 
washout period prior to global ischemia. At the end of each experimental protocol, the 
infarct size was assessed by TTC staining and infarct size was determined with using 
computerised planimetry, as detailed in the Methods section.  
2.4 Western Blots analysis 
Before the regional ischemic insult, the ventricular tissue from control, melatonin or 
resveratrol pretreated rat hearts, were excised, freeze clamped in liquid nitrogen and 
stored at -80ºC. Phosphorylated states of STAT-3 (phospho-STAT-3 Tyr 705) and total 
levels of STAT-3 were analysed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis with antibodies from cell signalling technology, as previously described 
in the methods section. Equal loading was verified with Ponceau staining and levels of 
phosphorylated proteins were normalised to their total protein levels performed in the 
same samples and under the same conditions but on a separate membrane.   
3. Statistical analysis 
Data are presented as mean ± SEM. N=6 per group. Comparisons between multiple 
groups were performed by one-way ANOVA followed by the Dunnet‟s post hoc test 
(Graph Pad Instat). A value of p<0.05 was considered as statistically significant. 
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4. Results 
4.1 Melatonin fails to protect in TNFR2-/- and STAT3-/- mice 
In Figure 30, isolated mouse hearts were subjected to 35 minutes of global ischemia 
followed by 45 minutes of reperfusion. The wild-type mice presented with an infarct of 
69.0±3.3% of the total heart. Melatonin pre-treatment reduced infarct size to 24.5±2.1% 
(p<0.001 compared with the ischemic control). TNFR2-deficient mice had an infarct size 
of 61.8±3.2% (ns. vs. wild-type control). Melatonin did not protect in TNFR2-deficient 
mice (ns vs TNFR2 control). Melatonin pre-treatment protected in STAT3 wild-type mice 
and presented with an infarct of 19.2±2.5%. In STAT3-deficient mice melatonin failed to 
protect (ns. vs wild-type control) (see Figure 30).  
 
Figure 30: Melatonin (75ng/ℓ)  protects against I/R. The protective effect of melatonin is abolished in 
TNFR2  and STAT3KO.***p<0.001 vs control 
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4.2 Melatonin fails to confer cardioprotection in the presence of the STAT 3 
inhibitor (AG490)  
Isolated rat hearts subjected to 30 minutes of regional ischemia and 120 minutes of 
reperfusion had an infarct of 44.4±2.8% (Figure 31). Pre-treatment with melatonin 
reduced the infarct size to 25.0±2.9% (p<0.001 versus control group).  
However, addition of AG490, the STAT-3 inhibitor, with melatonin abolished the 
protective effect of melatonin (Mel + AG = 36.83±8.7%, ns versus control group). 
AG490 given on its own did not alter the infarct size compared to the control group. 
CTL Mel Mel+AGAG
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Figure 31: The protective effect of melatonin is attenuated in the presence of AG490, STAT3inhibitor, in 
isolated rat hearts subjected to I/R.***p<0.001 vs.control, CTL (control), Mel+AG (coadministration of 
melatonin and AG490) Important note: these experiments were presented in my Master’s thesis but are 
presented here for better comprehension of the study.  
 
4.3 Melatonin increases STAT-3 phosphorylation in isolated rat hearts 
In the isolated rat heart, phosphorylated levels of STAT3 were assessed following 15 
minutes administration of melatonin prior to the ischemic insult. In the cytosol, there was 
no significant difference in phosphorylation of STAT3 between the control groups and 
the hearts treated with melatonin. However, in the nucleus, melatonin increased the 
phosphorylation of STAT3, on the tyrosine residue, by 75% compared to control 
(**p<0.01) (See Figure 32). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 73  
 
 
2.4
0.0
0.4
0.8
1.2
1.6
2.0
P
h
o
s
p
h
o
 S
T
A
T
-3
/
T
o
ta
l 
S
T
A
T
-3
CTL Mel
tSTAT
CTL Mel CTL Mel
CTL Mel
**
pSTAT
Cytosolic Nucleus
 
Figure 32: Role of melatonin (75ng/ℓ) on STAT3 phosphorylation **p<0.01 vs control (n=4). CTL (Control), 
Mel (Melatonin), pSTAT3 (phosphorylated STAT3 Tyr 705), tSTAT3 (total STAT3). Important note: these 
experiments were presented in my Master‟s thesis but are presented here for better comprehension of 
the study.  
 
4.4 Resveratrol fails to confer cardioprotection in TNR2-/- and STAT3-/- mice 
In Figure 33, isolated mouse hearts were subjected to 35 minutes of global ischemia 
followed by 45 minutes of reperfusion. The wild-type mice presented with an infarct of 
69.5±2.1 of the total heart. Resveratrol pre-treatment reduced infarct size to 25.2±2.5% 
(p<0.001 compared with the ischemic control). TNFR2-deficient mice had an infarct size 
of 65.2±2.3% (ns. vs. wild-type control). Resveratrol did not protect in TNFR2-deficient 
mice (ns vs TNFR2 control). Resveratrol pre-treatment protected in STAT3 wild-type 
mice and presented with an infarct of 25.2±2.5% (p<0.001 vs. wild-type). In STAT3-
deficient mice melatonin failed to protect (ns. vs. wild-type control) (see Figure 33).  
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Figure 33: Resveratrol (2.3mg/ℓ)  protects against I/R. The protective effect of resveratrol is abolished in 
TNFR2 KO and STAT3KO.***p <0.001 vs relative control. 
 
4.5 Resveratrol Fails to confer Cardioprotection in the presence of the STAT3 
inhibitor (AG490) 
Isolated rat hearts subjected to 30 minutes of regional ischemia and 120 minutes of 
reperfusion had an infarct of 48.8.±4.0% (Figure 33). Pre-treatment with resveratrol 
reduced the infarct size to 15.0±1.0% (p<0.001 vs. control). However, coadministration 
of AG490, the STAT-3 inhibitor, with resveratrol abolished the cardioprotective effect of 
resveratrol (Res + AG = 49.5± 6.9%, ns vs control group) (see Figure 34). AG490 given 
on its own did not alter the infarct size compared to the control group (ns vs. control).  
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Figure 34: The protective effect of resveratrol is attenuated in the presence of AG490 in isolated rat 
hearts subjected to I/R. CTL (Control), AG (AG490 STAT3 inhibitor), Res (Resveratrol), Res+AG (Co-
administration of resveratrol and AG490). ***p<0.001 vs. control. 
 
4.6 Resveratrol increases STAT-3 phosphorylation in isolated rat hearts 
In the isolated rat heart phosphorylated levels of STAT3 were assessed following 15 
minutes administration of resveratrol. In the cytosol, there was an increase in 
phosphorylated STAT3, on the tyrosine residue, by 50% between the control groups 
and those treated with resveratrol (*p<0.05).  In the nucleus there was a 71% increase 
in pSTAT3 with resveratrol treatment compared to control (**p<0.01) (see Figure 35). 
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Figure 35: Role of resveratrol (2.3mg/ℓ) on cytosolic and nuclear phosphorylation of STAT3. 
Phosphorylated STAT3 levels are  increased in the cytosol (*p<0.05 vs. control) and  in the nucleus 15 
minutes after treatment **p<0.01 vs respective control (n=4). CTL (Control), Res (Resveratrol), pSTAT3 
(phosphorylated STAT3 Tyro 705), tSTAT3 (total STAT3). 
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5. Discussion 
The present study demonstrates that a very low concentration of melatonin, 
corresponding to the concentration found in red wine, protects the heart against an IR 
injury. Furthermore, we demonstrate that both melatonin and resveratrol confer 
protection via the activation of the newly discovered SAFE pathway which involves the 
activation of TNFR2 and STAT3. Hence, both resveratrol and melatonin failed to protect 
against ischemia-reperfusion in hearts of TNFR2 deficient mice or STAT3-deficient 
mice. Similarly, the protection with resveratrol or melatonin in rat hearts was abrogated 
in the presence of AG490, an inhibitor of the STAT3 pathway. Furthermore, both 
resveratrol and melatonin pre-treatment were associated with an increased activation of 
STAT3 in the nucleus therefore suggesting an activation of STAT3 in the myocardium of 
treated rats. 
5.1 Melatonin, given at a similar concentration as present in red wine, can 
confer cardioprotection 
The cardioprotective effect of melatonin against IR was previously reported both in vitro 
and in vivo at concentration ranging from 1-50 μM (0.22mg/ℓ -11mg/ℓ) (Tan et al., 1998). 
These concentrations are up to a 1000 times higher than the physiological mammalian 
blood levels of melatonin which will generally oscillate between 10ng/ℓ during the day 
and 200ng/ℓ at night (Kaneko et al., 2000). The novelty of our work was to demonstrate 
that a physiological concentration of melatonin (75ng/ℓ), corresponding to the 
concentration found in natural food products such as red wine, can also protect the 
heart against an I/R insult. Our data support previous work demonstrating that 
endogenous melatonin contributes to cardioprotection with infarct size measured in 
pinealectomised rats subjected to ischemia-reperfusion being increased compared to 
normal rats (Hardeland et al., 2005). Melatonin is commercially available and prescribed 
to regulate the sleeping pattern at a dose ranging between 1 and 3mg per day. This 
dose of melatonin would require drinking more than 1000ℓ of wine per day! We 
acknowledge the fact that the amount of melatonin given directly to the isolated heart is 
higher than the amount that the heart would receive after ingestion of red wine, but half 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 78  
 
an hour after drinking 100mℓ of red wine, the amount of melatonin in the blood is 
increased by approximately 20% (Guerrero et al., 2008). 
5.2 Melatonin protects via the activation of the SAFE pathway  
As ROS contribute to I/R injuries, the cardioprotective effect of melatonin has been 
essentially attributed to its anti-oxidant capacities by scavenging ROS (Tan et al., 1998), 
limiting mitochondrial electron leakage and inhibiting the opening of the mitochondrial 
permeability transition pore opening (Tengattini et al., 2008). Melatonin can exert some 
cardioprotective properties independently of its anti-oxidant effect, by activation of the 
protein kinase B or inhibition of the proapoptotic p38 mitogen-activated protein kinase 
(Genade et al., 2008). 
 Activation of the prosurvival intrinsic SAFE pathway is required for the protection of 
both ischemic pre- and postconditioning, two powerful phenomena to protect against IR 
injury (Suleman et al., 2008), and also multiple cardioprotective drugs such as 
sphingosine-1 phosphate, ethanolamine, insulin, bradykinin or opioids also protect via 
this pathway (Somers et al., 2010). Using genetically modified animals, our data 
demonstrate for the first time that melatonin-induced cardioprotection requires the 
activation of two major components of the SAFE pathway, namely the cytokine TNFR2 
and the transcription factor STAT3.  
5.3 Resveratrol protects against I/R injury via the SAFE pathway 
In patients with coronary artery disease, dealcoholised red wine (DRW) decreased 
arterial stiffness (Wang et al., 2005) and in apolipoprotein E deficient mice, DRW limits 
atherosclerosis, thus providing conclusive evidence that red wine properties “go beyond 
alcohol”  (Wang et al., 2005).  
Our data confirm numerous previous reports demonstrating that a concentration of 
resveratrol at 2.3mg/ℓ protects against ischemia-reperfusion injury. Again, a limitation of 
our study and others is the fact that the amount of resveratrol given directly to the 
isolated heart is higher than the amount that the heart would receive after ingestion of 
red wine. Following an acute oral administration of red wine in rats (4 mℓ of an Italian 
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red wine containing 6.5mg/ℓ), the resveratrol concentration peaked at 20 g/ℓ in the 
plasma (Bertelli et al., 1998). However, chronic red wine consumption may be 
associated with higher concentrations than those measured with an acute treatment and 
several studies have demonstrated that resveratrol as low as 0.22mg/ℓ can exert a 
number of biological effects (Bhat et al., 2001). Additional in vivo and chronic animal 
studies are required to confirm that this effect can account for the cardioprotective effect 
of red wine. 
The mechanisms of protection for resveratrol have been extensively studied but still 
remain uncertain. Well known for its anti-oxidant properties (Hattorri et al., 2002),  the 
anti-ischemic effect of resveratrol is thought to be mediated via activation of nitric oxide, 
adenosine, Akt, Bcl-2 and inactivation of pro-apoptotic factors such as Bad and 
glycogen synthase kinase 3β (Xi et al., 2009). Our data delineate a novel prosurvival 
pathway that resveratrol can activate to limit IR injury, and we demonstrate that 
resveratrol can target the immune system to limit IR damage by activating TNFα.  
As both resveratrol and melatonin, at concentrations as found in red wine confer 
cardioprotection by activation of the SAFE pathway, we suggest that moderate 
consumption of red wine protects against IHD by activation of the SAFE pathway. 
However, additional experiments conducted in vivo with a chronic consumption of 
melatonin, resveratrol or red wine will be required to confirm our statement.  
Melatonin appears to be superior to resveratrol because a far larger quantity of 
resveratrol is required to obtain a protective effect. This may be due to the varying 
bioavailability of each compound present in red wine. Also, there may be a variety of 
interactions between the compounds present in red wine which are required to confer 
cardioprotection. However, the synergistic effects of these compounds remain elusive 
and require further investigation. 
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5.4 Summary 
In summary, the cardioprotective effect of an acute treatment with melatonin or 
resveratrol (at concentrations similar to red wine) is mediated via the activation of the 
SAFE pathway. Therefore, it is suggested that the moderate consumption of red wine 
may protect against IHD through the activation of the SAFE pathway via melatonin and 
resveratrol (see figure 36). However, additional experiments conducted in vivo with the 
regular chronic moderate consumption of melatonin, resveratrol or red wine will be 
required to confirm our statement.  
5.5 Limitations 
A major limitation of this study is that an isolated heart model was utilised. Therefore, 
the exact interaction of each compound and its bioavailability or half life in the body is 
unknown. Furthermore, the compounds were given acutely therefore further 
investigation is required pertaining to the long term beneficial effects of melatonin and 
resveratrol. In spite of these limiting factors, the study is still novel in demonstrating the 
mechanism involved in the cardioprotective effects of the individual compounds, 
resveratrol and melatonin. It may explain the mechanism involved in   red wine induced 
cardioprotection. 
6. Conclusion 
In conclusion, our data strongly suggest that low concentrations of melatonin and 
resveratrol given acutely can protect the heart against I/R injury and may contribute to 
the cardioprotective effects of red wine. Furthermore, we have delineated a novel 
mechanism by which melatonin and resveratrol protect the heart via the activation of the 
powerful prosurvival SAFE pathway, which involves the activation of both TNFα and 
STAT3. Our data provide exciting novel insight for the use of natural compounds in the 
treatment of cardiac disease. 
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Figure 36: Melatonin and resveratrol induced cardioprotection is mediated via the activation of 
the SAFE pathway.  
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E. Chapter 2: The role of melatonin in 
red wine induced cardioprotection 
against I/R injury. 
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1. Introduction 
Several epidemiological studies have shown that the moderate and chronic 
consumption of red wine confer cardioprotection (Maike-Krenz et al., 2012). However, 
the exact components present in red wine that contribute to this effect remain unclear. 
Resveratrol, alcohol (12%) and melatonin are the three potential candidates that may 
contribute to the beneficial effects of red wine induced cardioprotection. In Chapter 1, 
our data demonstrate that the acute administration of melatonin or resveratrol, at a 
concentration found in red wine, could confer cardioprotection in an ex vivo model of I/R 
injury. However, a major limitation of the study was that the experiments were 
performed ex vivo and melatonin and resveratrol were given directly to the isolated rat 
or mouse hearts. Therefore, the bioavailability of these compounds in the blood stream 
and the break down in the body were not taken into consideration. The interaction with 
hormones and the nervous system should also be mentioned as melatonin released 
from the pineal gland, in the brain. Therefore, whether the chronic administration of 
melatonin and resveratrol could protect in an in vivo setting remains unclear and raises 
the question as to whether melatonin present in red wine may contribute to the 
protective effect of red wine. However, it is difficult to credit melatonin exclusively, for 
the cardioprotective effects of red wine  and it is likely that a synergy of components 
enables the beneficial effects of red wine. 
Previous findings obtained during my Master‟s degree demonstrated that neither 
resveratrol, given as a chronic treatment for 10 days at similar concentration to that 
found in red wine, nor alcohol (6%), protected against I/R injury in an isolated rat heart 
model, see figure 37 (Lamont et al., 2012). However, the chronic moderate consumption 
of alcohol (12%) equivalent to that found in red wine was not tested.  
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Figure 37: Effect of chronic pretreatment with resveratrol (2.3mg/ℓ) and alcohol (6%). Resveratrol or 
alcohol did not improve functional recovery in an isolated rat heart model subjected to I/R. n=6 per group 
(Lamont et al.,2012). 
 
Therefore, whether melatonin (75ng/ℓ) or alcohol (12%) administered chronically in an in 
vivo model could protect the heart against I/R requires investigation. Our experiments 
conducted in Chapter 1 demonstrated that the acute treatment with melatonin protected 
against I/R injury via the activation of the SAFE pathway, which involves the activation 
of TNFα and STAT3. However, whether the regular consumption of red wine or 
melatonin could protect via the activation of the SAFE pathway is unknown. 
2. Aim 
The aim of the present study was to explore whether the chronic and moderate 
consumption of melatonin, given at a dose equivalent to the concentration obtained 
after 2-3 glasses of red wine per day, may protect against I/R injury via the activation of 
the SAFE pathway. Furthermore, we used inhibitors of melatonin receptors to explore 
whether melatonin may contribute to the cardioprotective effect of chronic and moderate 
consumption of red wine (see Figure 38). 
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Figure 38: Schematic of hypothesis: we propose that the chronic and moderate consumption of red wine 
confers cardioprotection via melatonin and the activation of the SAFE pathway. 
3. Materials and methods 
3.1. Animals 
All the experiments were conducted on male rats or mice and were performed in 
accordance with the Guide for Care and Use of Laboratory Animals published by the 
U.S. National Institutes of Health (NIH publication No. 85(23), revised 1996). All 
procedures were approved by the Animal Research Ethics Committee, University of 
Cape Town, under the ethics number 011/026, “Delineating the cardioprotective effect 
of red wine and its components in an in vivo mouse model of I/R injury and IHF.” 
3.2. Chronic treatment with wine, alcohol (12%) and melatonin  
The drinking water for controls was supplemented with either red wine (French 
Cabernet Sauvignon), alcohol 12% directly extracted from red wine, or melatonin 
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(75ng/ℓ) for 14 days. The different drinking solutions were prepared by adding one part 
of red wine, alcohol (12%) or melatonin to seven parts of drinking water (equivalent of 2-
3 glasses of red wine/day relative to body weight), as previously described (Lamont et 
al., 2012). The addition of the drugs had no effect on the liquid consumption of the rats 
or mice. All the solutions were made fresh daily and preliminary data were performed to 
ensure the well-being of the animals and that the drinking behaviour remained 
unaltered. Thereafter, the hearts were isolated and mounted onto the Langendorff 
perfusion system or an in vivo I/R injury was performed, as described in methods 
section. To explore the role of melatonin in red wine-induced cardioprotection, luzindole 
(melatonin 1 and 2 inhibitor, administered 1mg/kg, ip) or prazosin (2.5mg/kg, ip) were 
given for 14 days in the presence or absence of red wine or melatonin (see Figure 39). 
Red wine(equiv. 2-3 glasses/day), alcohol 
(12%), resveratrol (2.3mg/L), melatonin 
(75ng/L), water (control). Luzindole(1mg/kg) 
and prazozin (given ip; 2.5mg/kg).
Drinking water was supplemented for 14 days.
Infarct Size (IS) Western Blot (WB)
 
Figure 39: Design of study male rats or mice drinking water was supplemented with either red wine, 
melatonin or alcohol12 (%) for 14 days. Infarct size was assessed at the end of each perfusion protocol 
and on a separate set of heart western blots were performed.  
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3.3. Experimental protocol 
Wistar rats (230-300g) were treated for 14 days; thereafter the rats were anaesthetised 
with 60mg/kg intraperitoneal sodium pentobarbitone and 200 IU heparin. Hearts were 
excised rapidly and perfused retrogradely using the Langendorff perfusion technique at 
a constant pressure (100 cm H2O) as described previously in the methods section. 
 
3.3.1. Experimental protocol for in vitro model of I/R in isolated rat heart model 
After the chronic pretreatment, all rats underwent 30 minutes stabilisation followed by 
30 minutes global ischemia (at 37°C) and 60 minutes reperfusion. The different 
treatments were as follows, see fig 39; rats were treated with either: red wine equivalent 
to 2-3 glasses/day; alcohol (12%) melatonin (75ng/ℓ); prazosin (2.3 mg/kg/day, ip), a 
melatonin receptor 3 inhibitor in the presence or absence of red wine or melatonin; 
luzindole, a melatonin receptor 1&2 inhibitor (1mg/kg/day, i.p.), also given in the 
presence or absence of red wine or melatonin. An additional group was treated with AG 
490, an inhibitor of JAK/STAT-3 (10mg/kg, given i.p.) on its own, or co-administered 
with red wine.  
 
30 min Global Ischemia 60min Reperfusion30 min S
14 day 
pretreatment
 
Figure 40: Schematic representation of the experimental protocol. Rat hearts were subjected to 30 
minutes of S(stabilisation) and underwent 30 minutes of global ischemia followed by 60 minutes of 
reperfusion. At   the end of the experiments the hearts were removed for infarct size.  
 
 
The functional parameters were measured throughout the protocol. At the end of the 
protocol infarct size was assessed. Additional groups were performed for Western Blot 
analysis; hearts were collected prior to the ischemic insult, as mentioned in the methods 
section.   
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3.3.2 Experimental protocol for in vitro I/R injury in an isolated mouse model 
TNF-deficient mice and their littermate controls (TNF-Wild types), as well as STAT-3 
cardiomyocyte-specific mice and their littermate controls were used. All mice were used 
between 12-16 weeks. The mice were pretreated for 14 days with either red wine, 
melatonin or plain drinking water, as described in section 3.1.1 of this chapter. The mice 
were anaesthetised and mounted onto the perfusion system, as described in the 
methods section. Thereafter, the hearts underwent 30 minutes stabilisation followed by 
35 minutes global ischemia at 37°C and 40 minutes reperfusion. 
 
35 min Global Ischemia 40min Reperfusion20 min S
14 day 
pretreatment
 
Figure 41: Schematic representation of the experimental protocol. Mouse hearts were subjected to 20 
minutes S (stabilisation) and underwent 35 minutes of global ischemia followed by 40 minutes of 
reperfusion. Infarct size was assessed at the end of all experiments. 
 
3.1.3 Experimental protocol for in vivo mouse I/R model  
C5BL6 mice were pre-treated for 14 days with either: red wine, melatonin (75ng/ℓ) or 
water (as described in section 3.1.1). Mice were anaesthetised with a combination of 
ketamine (0.06mg/mℓ) and xylazine (2mg/mℓ); the final concentration of both was 
0.01mℓ/g (Lim et al., 2007). The mice were intubated for artificial respiration, at 120 
strokes/minutes and 220ul stroke volume, using a minivent and supplemental oxygen 
was supplied. Thereafter, a left anterior thoracotomy was performed in the third 
intercostal space. The left ascending coronary artery was ligated with (8.0 ethilon, nylon 
suture black filament), 2 mm below the tip of the left auricle. A snare was created for 30 
minutes of ischemia and then released for 120 minutes of reperfusion. Evans blue was 
injected into the left ventricle to delineate dead tissue. The hearts were stored at -4º and 
later sectioned and stained with TTC, as previously described in the methods section. 
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4 Western Blots analysis 
Before the ischemic insult, the ventricular tissue from control, melatonin- or resveratrol-
pretreated rat hearts, were excised, freeze-clamped in liquid nitrogen and stored at -
800C. Phosphorylated states of STAT-3 (phospho-STAT-3 Tyr 705) and total levels of 
STAT-3 were analysed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
with antibodies from cell signalling technology, as previously described in the methods 
section. Equal loading was verified with Ponceau staining and levels of phosphorylated 
proteins were normalised to their total protein levels performed in the same samples and 
under the same conditions but on a separate membrane.  
 Statistical analysis 
Data are presented as mean ± SEM. N=6 per group. Comparisons between multiple 
groups were performed by one-way ANOVA followed by the Dunnet‟s post hoc test 
(Graph Pad Instat). A value of p<0.05 was considered as statistically significant. 
 
6 Results 
6.1. Alcohol (12%) fails to protect the rat heart against I/R injury 
Prior to the ischemic insult the control hearts presented a left ventricular developed 
pressure (LVDP) of 87±1 mmHg, heart rate (HR) of 340±17 beats/minute and a 
coronary flow (CF) of 13±1mℓ. The treatment with either red wine or alcohol (12%) had 
no effect on the hearts prior to I/R. However, after 30 minutes of ischemia and 30 
minutes of reperfusion the values were reduced for the control hearts to; LVDP (23±3 
mmHg), HR (227±20 beats/minute) and CF (5.5±0.3 mℓ). Red wine pre-treatment 
improved LVDP to 38±3 mmHg (*p<0.05 vs. control). Pre-treatment with alcohol (12%) 
had no effect on the functional parameters after ischemia-reperfusion injury (ns. vs. 
control). Of note, the treatment with red wine or alcohol did not affect the body weights 
of the animals.  
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Table 4: Haemodynamic parameters of isolated perfused rat hearts subjected IR and pretreated with 
wine or alcohol 
 
Pre-ischemic Reperfusion 5 minutes   Reperfusion 30 minutes 
 
LVDP (mmHg) 
Control   87 ± 1   16 ± 2   23 ± 3 
Wine    88 ± 3   26 ± 3*  38 ± 3* 
Alcohol 12%   87 ± 6   10 ± 4   17 ± 2 
 
Heart rate (bts/minute) 
Control   340 ± 17  192 ± 32  227 ± 20 
Wine 12%   300 ± 9  250 ± 37  253 ± 29 
Alcohol 12%   328 ± 15  232 ± 66  286 ± 36 
 
Coronary Flow (mℓ/minute) 
Control   13.0 ± 1.1 7.3 ± 0.4  5.5 ± 0.3 
Wine 12%   11.8 ± 1.4  10.0 ± 0.9  6.7 ± 0.4 
Alcohol 12%   10.4 ± 0.6  9.2 ± 0.5  7.0 ± 0.6 
   
Parameters measured prior to ischaemia (pre-ischaemic), after 5 and 30 minutes of reperfusion. Values 
are mean ± standard error of mean (SEM) (n=6). LVDP (left ventricular developed pressure), HR (heart 
rate), CF (coronary flow), bts/minute (beats/ minute). *p<0.05 vs. control 
 
6.2. Chronic and moderate administration of red wine and melatonin confer 
cardioprotection in both an in vivo and an ex vivo model 
In the in vivo model, mouse hearts were pretreated with either red wine or melatonin for 
14 days. Thereafter, the mice were anaesthetised, ventilated and the chest was 
opened. The hearts underwent 35 minutes ischemia and 120 minutes reperfusion. The 
mice that were given plain drinking water presented an infarct of 60.0±2.3%. The red 
wine dramatically reduced infarct size from 60.0±2.3% to 23.3±1.8% compared to 
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controls (p<0.001). Similarly, melatonin given on its own reduced infarct size to a similar 
extent to red wine 20.1±1.7%, (p<0.001 compared to control), see figure 42. These data 
were confirmed in an ex vivo model, where the mouse hearts were isolated and 
mounted onto the perfusion system and subjected to 35 minutes of ischemia and 40 
minutes of reperfusion. Hearts that were pretreated with red wine had a smaller infarct 
than the control group of (19.8±2.5% and 47.3±3.5% respectively, p<0.001). Similarly, 
melatonin reduced infarct size to 17.9±2.0 versus the control (p<0.001). Of note, the 
treatment with red wine or melatonin did not affect the weights of the animals. 
 
0
10
20
30
40
50
60
70
CTL Melatonin Wine CTL Melatonin Wine
In
fa
rc
ts
iz
e
 (
%
)
In Vivo Ex Vivo
***
***
***
***
*** p<0.001  
Figure 42: Red wine and melatonin protect against I/R in an in vivo and an ex vivo  mouse model. CTL 
(Control). ***p<0.001 vs. respective control. 
 
 
6.3. The effect of melatonin receptors inhibitors on red wine-induced 
cardioprotection.  
To explore whether melatonin may contribute to red wine induced cardioprotection, rats 
were treated for 14 days with either wine or melatonin in the presence or absence of the 
melatonin inhibitors (luzindole, inhibits receptor 1 and 2 or prazosin, inhibits receptor 3 
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all administered ip) and then subjected to an I/R injury on the isolated rat heart 
perfusion model. 
6.3.1. The effect of luzindole of red wine induced protection 
The chronic moderate consumption of red wine reduced infarct size from 58.8±3.8% to 
19.2±2.6% (p<0.01 vs. control) (see Figure 43). Similarly, melatonin reduced infarct size 
to 19.9± 4.0% (p<0.01 vs. control). Luzindole on its own was similar to the control (ns 
vs. contol). Melatonin lost its infarct sparing ability in the presence of luzindole and 
presented with an infarct of 58.9±5.0% (ns vs. control). On the contrary, the protective 
effect of red wine persisted in the presence of luzindole (ns vs. control). The chronic 
moderate consumption of red wine reduced infarct size from 58.8±3.8% to 19.2±2.6% 
(p<0.01 vs. control) (see Figure 43). Similarly, melatonin reduced infarct size to 19.9± 
4.0% (p<0.01 vs. control).  
 
6.3.2. The effect of prazosin on red wine induced rotection 
In separate experiments control hearts had an infarct of 80±4.1% (see Figure 44). The 
prazosin treatment on its own presented with an infarct of 79.8±3.0% (ns vs. control), 
these data were performed separately and are displayed on a separate graph. When 
prazosin was coadministered with red wine, the protective effect of red wine was 
attenuated (p<0.001 vs. red wine). Similarly, the protective effect of melatonin was 
attenuated with prazosin treatment compared to melatonin given on its own (p<0.01 vs. 
melatonin). The treatment with prazosin alone was missing in figure 43 and additional 
experiments were performed several months later using a different perfusion system. 
Although infarct size was increased when compared to controls on figure 43, prazosin 
alone had no effect compared to controls (figure 44).  Of note, none of the treatments 
affected the body weights of the animals prior to I/R. 
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Figure 43: The effect of luzindole on red wine induced cardioprotection in the isolated rat heart model. 
CTL (Control), Mel (Melatonin), Luz (Luzindole), W (Wine).***p<0.01 vs. control, ++ p<0.01 vs. melatonin, 
$ p<0.01 vs wine. 
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Figure 44: The effect of prazosin on red wine induced cardioprotection in the isolated rat heart model. 
***p<0.001 vs. control, $p<0.001 vs. wine, ** p<0.001 vs melatonin. These experiments were performed 
several months later on a different perfusion protocol as compared to figure 43.P (Prazosin). 
 
6.4. Chronic treatment with red wine or melatonin fails to confer 
cardioprotection in TNF receptor 2 deficient mice  
To explore the role of the SAFE pathway in red wine or melatonin induced 
cardioprotection, we used in TNFR2 knockout mice subjected to an ex vivo model of I/R 
injury. 
In Figure 45, isolated wild type control mice received plain drinking water and were 
subjected to 35 minutes of global ischemia followed by 45 minutes of reperfusion 
presented an infarct of 49.9±5.0%. Red wine pre-treatment for 14 days reduced infarct 
size in wild-types to (19.9±4.0%; p<0.001 vs. control). Similarly, melatonin pre-treatment 
reduced infarct size to 15.3±3.2% compared to the ischemic control.  
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The protective effect of both red wine and melatonin was lost in TNF receptor 2-
deficient mice (ns. vs. control).  
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Figure 45: The cardioprotective effect of red wine and melatonin is lost in TNF receptor 2 deficient mice in 
an ex vivo model of I/R. (n=6 for all groups). ***p<0.001 vs water CTL (control). 
 
6.5. Chronic treatment with red wine and melatonin fails to confer 
cardioprotectio  in STAT3 knockout mice 
In figure 46, isolated wild type control mice that received plain drinking water and that 
were subjected to 35 minutes of global ischemia followed by 45 minutes of reperfusion 
presented an infarct of 49.7±4.5%. Red wine pre-treatment for 14 days reduced infarct 
size in wild-type hearts to (18.7± 3.2%; p<0.001 vs. control). Similarly, melatonin pre-
treatment reduced infarct size to 15.8±3.8% compared to the ischemic control 
(p<0.001). The protective effect of both red wine and melatonin was lost in STAT3- 
deficient mice (ns. vs. control).  
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Figure 46: The cardioprotective effect of red wine and melatonin is lost in STAT 3 cardiomyocyte deficient 
mice subjected to an ex vivo model of I/R injury. (n=6 for all groups).***p<0.001 vs. water control 
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7. Discussion 
7.1. Summary 
The results show that the regular moderate consumption of melatonin, similar to that 
present in red wine, and red wine on its own (equivalent to 2-3 glasses/day) protect the 
heart against I/R injury in both an in vivo and an ex vivo setting. The protective effect of 
both red wine and melatonin were partially abolished with prazosin. Therefore 
suggesting that melatonin contributes to the cardioprotective effect of regular moderate 
red wine consumption, against I/R injury furthermore our data conducted in the TNFR2- 
and STAT3-deficient mice suggest that the protective effect may be mediated via the 
activation of the newly discovered SAFE pathway. 
7.2. Melatonin and red wine confers cardioprotection in vivo and ex vivo 
Over the past few years, there has been a growing interest in red wine-induced 
cardioprotection. Evidence from epidemiological studies demonstrates reduced 
cardiovascular risk in France even though they consume foods that are high in 
saturated fat (St Leger et al., 1979). Experimentally, most studies exploring the role of 
red wine are completed on red wine extracts, such as the popular polyphenol 
resveratrol, but not the red wine itself (Bertelli et al.,1998, Covas et al., 2010). Very high 
concentrations of resveratrol (10uM), which are not within the expected therapeutic 
range after 2-3 glasses of red wine/day are administered, therefore, suggesting, the 
presence of other components in red wine that confer its protective effect. Melatonin 
administration at a high concentration of 40µg/ℓ on the working heart model, protects 
against IR injury and reduces infarct size (Lochner et al., 2006). In the previous chapter, 
we have suggested that low concentrations of melatonin, similar to that found in red 
wine (75ng/ℓ) can protect against IR injury (Lamont et al., 2011). Melatonin is present in 
both red and white wine, but is more predominant in red wine (Guerrero et al., 2009); 
therefore it has been suggested that the protective effect of wine may be dependent on 
the melatonin concentration. Our present data show that, the regular and chronic 
administration of melatonin for 14 days mimics the human setting as far as possible. It 
has been shown for the first time to our knowledge that the regular moderate daily 
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consumption of melatonin at low concentrations can protect the heart against ischemia-
reperfusion injury to a similar extent as red wine given on its own, in both an ex vivo and 
an in vivo model. The dose used in our model is almost a thousand times lower the 
pharmacological doses used in melatonin tablets ranging from 1-3mg. Furthermore, it is 
important to note that our concentrations of melatonin correspond to physiological 
ranges of plasma melatonin levels (Kaneko et al., 2000). 
7.3. The role for melatonin in red wine induced cardioprotection is mediated via 
melatonin receptor 3   
MT1 and MT2 are G protein couple receptors that inhibit adenylyl cyclase activity in 
different parts of the body, including the brain, heart, liver, kidney a d retina (Zhao et 
al., 2002). Melatonin receptor 3 (MT3) is a putative receptor idely spread in the 
hamster brain and peripheral tissues, but very little is known about the beneficial 
properties of this receptor. 
7.3.1. The effect of luzindole on red wine induced cardioprotection 
It is well documented that melatonin-induced protection is mediated via either melatonin 
1 or 2 receptors (MT1 and MT2) (Genade et al., 2008). It has even been postulated that 
it is not a membrane-bound receptor but rather a QR enzyme that influences 
vasoconstriction and immunological function in humans (Mailliet et al., 2005) Firstly, we 
explored the role of MT1 and MT2, with an antagonist luzindole, in red wine-induced 
protection. It has been suggested that luzindole may have anti-oxidant effect on its own 
(Mathes et al.,2008), therefore different concentrations were used to ensure no 
cardioprotective properties of the inhibitor on its own (high concentrations 5mg/kg done 
during my Masters research ,and lower concentrations 1mg/kg in the present study). 
Luzindole inhibited the protective effect of melatonin suggesting that melatonin on its 
own may protect via MT1 or MT2, but failed to block the protective effect of red wine, 
therefore suggesting that the protective effect of low concentration of melatonin in red 
wine is not mediated via MT1 or MT2 and stimulation of these receptors may be dose 
specific. The pharmacodynamics of luzindole in conjunction with the various 
components in red wine is unknown and may reduce the efficacy of the inhibitor.  
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Furthermore, if any of the compounds in the red wine share a similar anatomical 
structure to luzindole there may be competition for the same site and if so wine induced 
cardioprotection elicited in the presence or absence of luzindole. 
7.3.2. The effect of prazosin on red wine-induced cardioprotection 
It has been demonstrated that at high concentrations (40µg/ℓ) the cardioprotective effect 
of melatonin is receptor dependent (Genade et al., 2008). Consequently we explored 
the role of MT3. To determine the role of the putative MT3, prazosin was administered 
in the presence or absence of red wine or melatonin. The infarct-sparing ability of 
melatonin was abolished in the presence of prazosin. Furthermore, the protective effect 
of red wine was diminished, with melatonin inhibition. The protective effect of melatonin 
may be dependent of its receptors, if MT3 is actually an unbound enzyme. The fact that 
prazosin partially attenuated the infarct sparing capacity of red wine suggest that a 
synergy of other compounds present in red wine may contribute to its cardioprotective 
effect. Interestingly, prazosin also inhibits the adrenoreceptors, located in the vascular 
smooth cells (Dubocovich & Markowska 2005). These receptors are responsible for the 
vasoconstrictive effect of norepinephrine, and when inhibited with prazosin blood 
pressure, anxiety and sleep disorders are diminished (Galli-Carminati et al., 2009). 
Interestingly, the production of melatonin at night is triggered by the release of 
norepinephrine which triggers the sympathetic nerves in the pineal perivasculature. This 
promotes the activation of the α and β adrenoreceptors and the secondary messenger 
cyclic adenosine diphosphate, which drives the production of melatonin (Sun et al., 
2002; Gonzalez et al., 2012) The adrenoreceptors play a key role in the regulation of 
the 5 hydroxyserotonin (5-HT), the precursor for melatonin formation. The β 
adrenoreceptor is where 5-HT is synthesised and α adrenoreceptors is where 5-HT is 
released. When 5-HT is released, it must undergo decarboxylation to form N-
acetylserotonin, the rate limiting step during melatonin biosynthesis (Sun et al., 2002; 
Gonzalez et al., 2012). Thus, the inhibition of the adrenoreceptors with parasozin will 
reduce the synthesis and release of 5-HT, and in turn, will reduce melatonin synthesis. 
Thus the effect of prazosin on melatonin may be independent of its melatonin receptors 
as it may directly affect the production of endogenous melatonin.This remains unclear 
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and requires further investigation with ex vivo experiments. Nonetheless, 
pharmacological inhibitors are non selective so to determine the exact role of the 
melatonin receptors; melatonin receptor knockout mice should be used. Unfortuntately 
there are no MT3 knockout mice available.  
7.4. Melatonin- and red wine-induced cardioprotection is mediated via the SAFE 
pathway  
Melatonin is a powerful anti-oxidant 100x more effective than vitamin E (Tan et al., 
1999). Melatonin protects against I/R injury. This protective effect may be mediated by 
melatonin anti-oxidant qualities. In 2010, it was demonstrated that melatonin can exert 
its protective effect through the inhibition of the mitochondrial permeability pore opening 
(Tengetti et al., 2008). Other studies have shown that melatonin can protect via the 
activation of the PI3k/Akt pathway and this protective effect is mediated via its 
receptors, MT1 and MT2 (Genade et al., 2008). In Chapter 1, we have shown that 
melatonin activates the SAFE pathway via the innate immune system, TNFα and its 
downstream target STAT3 (Lamont et al., 2011). Our present data demonstrate for the 
first time that the moderate daily consumption of red wine or low doses of melatonin 
requires the activation of the prosurvival SAFE pathway for cardioprotection. This effect 
is most likely mediated via the putative MT3 receptor. Furthermore, a well known 
downstream target of the SAFE pathway is the activation of the mPTP pore (Boengler et 
al., 2008), it can be postulated that a low dose of melatonin as attained by the regular 
and moderate consumption of red wine may protect via the closing of the mPTP. 
 
8. Limitations of the study  
Red wine and melatonin were diluted in the drinking water of either mice or rats. The 
body weight and normal consumption of each animal was taken into careful 
consideration prior to administration. However, there were 3-4 animals in each cage so 
the exact consumption by each animal remains unknown. For future studies oral gavage 
would be a better alternative to ensure standardized treatment and to better mimic a 
clinical setting. Furthermore, the melatonin concentration should be measured in the 
blood plasma after red wine consumption to better determine melatonin‟s bioavailability. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 101  
 
These studies also used relatively young healthy rats/mice in the model of I/R injury but 
in reality, people who suffer from an acute myocardial infarction are typically middle to 
old aged with, hypertension or obesity. Therefore, the contraindications of moderate red 
wine or melatonin consumption due to possible interaction with medications, including 
β-blockers, aspirin or statin therapy are unknown and require further investigation. 
9. Summary and Conclusion  
Our data provide strong evidence that the daily moderate consumption of red wine can 
protect the heart against I/R injury. Also, melatonin administration at concentrations 
corresponding to the one found in red wine can confer cardioprotection. Most 
importantly the inhibition of melatonin in red wine, results in the attenuation of red wine 
induced protection, thus strongly suggesting that melatonin is a key player but not the 
only component that contributes to red wine-induced cardioprotection. Furthermore, the 
cardioprotective effect of both melatonin and red wine are mediated via the activation of 
the prosurvival SAFE pathway. Our data provide a safe therapy in treating 
cardiovascular disease in low- and high-income settings as melatonin is a cheap 
compound that is widely available over the counter in many countries, see figure 47. 
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Figure 47: Melatonin contributes to red wine induced protection via the activation of the SAFE pathway. 
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F. Chapter 3: Melatonin protects in a 
model of ischemic heart failure 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 103  
 
1. Introduction 
HF is a complex syndrome involving a variety of structural and functional changes. 
These changes impair the ability of the heart to pump and eventually render the heart 
incapable of maintaining normal physiological circulation (McDonagh et al., 2011). 
Patients with an acute myocardial infarction will often develop ischemic heart failure. 
Unfortunately, there are no real therapies for the prevention of IHF. 
Previous studies performed in chapter 1, showed that an acute perfusion of melatonin, 
can protect the heart against ischemia-reperfusion injury. In Chapter 2, we have 
demonstrated that a regular consumption of melatonin, given at physiological 
concentrations for 14 days, reduced I/R injury in an isolated heart model. These findings 
were further corroborated in an in vivo model of I/R. Interestingly, this protective effect 
was mediated via the activation of the prosurvival signalling pathway, the survivor 
activating factor enhancement (SAFE) pathway. STAT3, a major component of the 
SAFE pathway may play a pivotal role in HF as STAT3 deficient mice develop HF. 
Therefore, whether, the SAFE pathway could protect in a model of ischemic HF requires 
investigation.  
In the literature patients with CAD and MI exhibit a reduction in melatonin levels at night 
(as reviewed by Paulis & Simko, 2007). Long-term studies performed in patients with 
high blood pressure displayed an improved outcome with melatonin supplementation 
(2.5mg/day for 14 days) (as reviewed by Paulis & Simko 2007; Paulis et al., 2010). 
However, whether chronic melatonin administration could be used as a therapy in 
ischemic HF remains unclear and whether the protective effect could be mediated via 
the chronic action of the SAFE pathway is unknown. 
2. Aim  
Therefore, the aim of the current study was to extend the findings from a model of I/R to 
a model of ischemic HF and to determine whether chronic treatment with melatonin, at 
the concentration found in 2-3 glasses of red wine per day, can confer cardioprotection 
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against ischemic HF. Furthermore, we propose that melatonin-induced cardioprotection 
in ischemic HF may be mediated via the modulation of the SAFE pathway.   
Melatonin
Protects against 
ischemia-reperfusion 
injury via the SAFE 
pathway!
1) Can melatonin 
protect in ischemic 
heart failure 
2) via the SAFE 
pathway?
 ?
 
Figure 48: Proposed hypothesis: Can melatonin protect in a model of ischemic HF via  the SAFE 
pathway. 
 
3. Methods 
3.1. Animals 
All the experiments conducted on mice (12-14 weeks) were performed in accordance 
with the Guide for Care and Use of Laboratory Animals published by the U.S. National 
Institutes of Health (NIH publication No. 85(23), revised 1996). All procedures were 
approved by the Animal Research Ethics Committee (UCT) under the ethics number 
011/026, “Delineating the cardioprotective effects of red wine and its active components 
in an in vivo mouse model of ischemic HF”. Animals had access to food and water ad 
libidum. 
3.2. Heart failure model 
After the administration of anaesthesia (isoflurane mixed with oxygen), a tracheotomy 
was performed and the mice were intubated. With a lack of a pedal reflex, a left anterior 
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thoracotomy was performed in the third intercostal space and the pericardium removed. 
The left ascending coronary artery was ligated as described in Chapter 2. 
3.2.1. Experimental protocol  
TNF-/- mice, STAT3 -/- mice their littermate controls and C5/BL6 mice were pre-treated 
for 5 days with either: water, melatonin (75ng/ℓ), water and AG490, in the presence or 
absence of melatonin (10mg/kg, ip). To assess the hemodynamic function the mice 
underwent echocardiography prior to the permanent ligation, for baseline values with or 
without treatment. Thereafter, the left ascending coronary artery was ligated and the 
mice were further treated with plain drinking water, melatonin with or without AG490. 
After 28 days, the mice were anaesthetised with isoflurane and oxygen. Another 
echocardiogram was performed prior to termination. The heart was excised and stored 
in 10% formalin for future histological assessment. Body weight, heart weight and tibia 
length were all assessed as measures for HF.  
Statistical analysis 
Data are presented as mean ± SEM. N=6 per group. Comparisons between multiple 
groups were performed by one-way ANOVA followed by the Dunnet‟s post hoc test 
(Graph Pad Instat). A value of p<0.05 was considered as statistically significant. 
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Figure 49:Experimental protocol melatonin was administered in the drinking water of wild-types, STAT3 
KO or TNF KO mice as well as wild-type littermate controls. In the C5BL6 mice, melatonin was 
administered in the presence or absence of AG490 (10mg/kg), a STAT3 inhibitor five days prior to the 
permanent ligation and throughout the 28-day period, post ligation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 107  
 
4. Results 
 
4.1. The cardioprotective effects of melatonin against ischemic HF in TNF KO 
mice 
4.1.1. Heart weight/Body weight 
As depicted in the Table 5, the wild-type controls that were given plain drinking water 
that were subjected to a 28-day permanent ligation, had a heart-weight/body-weight 
(HW/BW) ratio of 11.9±2.3. The melatonin treatment in wild-type mice reduced HW/BW 
to 6.7±3.1 (*p< 0.05 vs. control). In the TNF KO mice that were given plain drinking 
water presented with a HW/BW was 11.5±1.4. TNF KO that had been treated with 
melatonin had a reduced HW/BW of 6.5±2.6 (p<0.05 vs. control).  
4.1.2. Tibia length/Body weight 
As depicted in the Table 5, the wild-type controls that were given plain drinking water 
that were subjected to 28-day permanent ligation, had a tibia-length/body-weight 
(TL/BW) ratio of 82.9±2.2. The melatonin treatment in wild-type mice reduced TL/BW to 
62.3±1.8 (*p< 0.05 vs. control). In TNF KO mice that were given plain drinking water 
had TL/BW of 77.2±3.0. The TNF KO that had been treated with melatonin had a 
reduced HW/BW of 58.4±2.9 (*p<0.05 vs. control).  
 
Table 5: The heart weight/body weight (HW/BW) vs. tibia length/body weight (TL/BW) in TNF 
KO and wild-type littermate controls 
Control Melatonin Control Melatonin Control Melatonin Control Melatonin
11.9 ± 2.3 6.72 ± 3.1 11.5 ±1.4 6.55 ± 2.6 82.9 ±2.2 62.3 ± 1.8 77.2 ± 3.0 58.4 ± 2.9
Wildtypes TNF KO 
Heart Weight/Body Weight 
(ratio)
* *
Tibia length/Body Weight 
(ratio)
**
*p<0.05 vs control
WildtypesTNF KO 
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4.1.3. Echocardiography 
Hemodynamic parameters of all mice were assessed by echocardiography. Mouse 
hearts were subjected to a permanent ligation. In Figure 50, the wild-type mice given 
plain drinking water presented with an EF of 89.1± 1.5% and a FS of 54.0±2.0%. 
Melatonin treatment had no effect on the wild-type mice prior to ligation (ns. vs. control). 
In Figure 51, TNF KO mice that received plain drinking water presented with an EF of 
91.1± 1.0% and FS of 54±2.9%. Melatonin treatment had no effect on the TNF KO mice 
prior to ligation (ns. vs control).  
In Figure 51, the wild-type controls had an EF of 49.3±0.9% and FS of 23±2.8%, post 
ligation. The wild-types that received melatonin treatment had an improved EF of 
74.4±3.1% and FS of 38.9±2.8% (p<0.001 vs control). The TNF KO mice that received 
plain drinking water had an EF of 60±4.0% and FS of 28.3±1.9%. The TNF KO that 
received melatonin treatment had an improved EF of 82±1.4% and FS of 45±1.9% 
(p<0.001 vs. controls) (see figure 52). 
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Figure 50: EF (ejection fraction) prior to ligation. WT (wild-types) and TNF KO mice were treated with 
either water or melatonin for 5 days. 
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Figure 51: FS (fraction shortening) prior to ligation. WT (wild-types) and TNF KO mice were treated with 
either water or melatonin for five days. 
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Figure 52:. Ejection fraction after 28 days of permanent ligation. WT (wild-types) and TNF KO mice were 
treated with either water or melatonin for 28 days.**p<0.001 vs. respective water controls 
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Figure 53: Fractional shortening (FS) after 28 days of permanent ligation. WT (wild-types) and TNF KO 
mice were treated with either water or melatonin for 28 days. **p<0.001 vs. repective water controls. 
 
4.4. The cardioprotective effects of melatonin protects against ischemic HF in 
STAT3KO mice 
4.4.1. Heart weight/body weight 
As depicted in the Table 6, the wild-type controls that were given plain drinking water 
that were subjected to a 28-day permanent ligation, had a heart-weight/body-weight 
(HW/BW) ratio of 12.1±0.3. The melatonin treatment in wild-type mice reduced HW/BW 
to 6.4±1.9 (*p< 0.05 vs. control). In the STAT3 KO mice that were given plain drinking 
water HW/BW, was 9.7±3.2. STAT3 KO that had been treated with melatonin had a 
reduced HW/BW of 6.6±2.8 (*p<0.05 vs. control).  
4.4.2.  Tibia length/Body weight 
As depicted in the table 6,  the wild-type controls that were, given plain drinking water 
that were subjected to a 28 day-permanent ligation, had a tibia-length/body-weight 
(TL/BW) ratio of 61.0±2.6. The melatonin treatment in wild-type mice reduced TL/BW to 
68.1±4.0. In STAT3 KO mice that were given plain drinking water had a TL/BW of 
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89.3±3.5. STAT3 KO treated with melatonin was similar to the plain drinking water 
control. 
 
Table 6: The heart weight/body weight (HW/BW) vs. tibia length / body weight (TL/BW) in STAT3 KO and 
wild-type littermate controls. 
Control Melatonin Control Melatonin Control Melatonin Control Melatonin
12.1 ± 0.3 6.4 ± 1.9 9.7±3.2 6.6 ± 2.8 61.0 ± 2.6 68.1 ± 4.0 89.3 ± 3.5 70.2 ± 2.8
Wildtypes STAT3  KO 
Heart Weight/Body Weight 
(ratio)
*
Tibia length/Body Weight 
(ratio)
*p<0.05 vs control
WildtypesSTAT3 KO 
 
4.4.3. Echocardiography 
Hemodynamic parameters of all mice were assessed by echocardiography. Mouse 
hearts were subjected to a permanent ligation. In Figure 54, the wild-type mice given 
plain drinking water presented an EF of 89.1± 1.5% and a FS of 54.0±2.0%. Melatonin 
treatment had no effect on the wild-type mice prior to ligation (ns. vs. control). In Figure 
54, STAT3 KO mice that received plain drinking water presented with an EF of 91.1± 
1.0% and FS of 54±2.9%. Melatonin treatment had no effect on the TNF KO mice prior 
to ligation (ns. vs control).  
In Figure 56, the wild-type controls had an EF of 49.3±0.9% and FS of 23±2.8%,  post 
ligation. The wild-types that received melatonin treatment had an improved EF of 
74.4±3.1% and FS of 38.9±2.8% (p<0.001 vs control). The STAT3 KO mice that 
received plain drinking water had an EF of 60±4.0% and FS of 28.3±1.9%. The STAT3 
KO that received melatonin treatment had an improved EF of 82±1.4% and FS of 
45±1.9%, post ligation (p<0.001 vs. controls) (see Figures 56 and 57).  
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Figure 54: EF (ejection fraction) prior to ligation. WT (wild-types) and STAT3 KO mice were treated with 
either water or melatonin for five days. 
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Figure 55: FS(fractional shortening) prior to ligation. WT (wild-types) and STAT3 KO mice were treated 
with either water or melatonin for five days. 
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Figure 56: :. Ejection fraction after 28days of permanent ligation. WT (wild-types) and STAT3 KO mice 
were treated with either water or melatonin for 28 days.***p<0.001 vs.repective water controls 
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Figure 57 : FS (fractional shortening) after 28days of permanent ligation. WT (wild-types) and STAT3 KO 
mice were treated with either water or melatonin for 28 days.***p<0.001 vs.repective water controls 
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4.5. Inhibition of STAT3 with AG490 does not abolish Melatonin induced 
cardioprotection  
4.5.1. Heart weight/Body weight 
As depicted in the table 7, controls that were given plain drinking water were subjected 
to 28 day permanent ligation, had a heart-weight/body-weight (HW/BW) ratio of 
12.0±1.9. The melatonin treatment in wild-type mice reduced HW/BW to 6.1±3.8 (*p< 
0.05 vs. control). AG490, a STAT3 inhibitor had a HW/BW of 10.2±3.6. 
Coadministration of melatonin and AG490 had a HW/BW of 6.6±4.0 (ns vs. control).  
 
4.5.2. Tibia length/Body weight 
As depicted in the Table 7, the controls given plain drinking water were subjected to 28 
day permanent ligation, had a tibia length /body weight (TL/BW) ratio of 55.0±2.3. The 
melatonin treatment had no significant effect (ns. vs. control). The coadministration of 
AG490 had no effect on tibia length (ns vs control). However, the coadministration of 
melatonin and AG490 reduced TL/BW to 70.0±0.8 (*p<0.05 vs. control).  
 
Table 7: The heart weight/body weight (HW/BW) vs. tibia length/body weight (TL/BW) in wild-type 
littermate mice. 
Control Melatonin Control Melatonin Control Melatonin Control Melatonin
12.0 ± 1.9 6.1 ± 3.8 10.2±3.6 6.6 ± 4.0 55.0 ± 2.3 69.5.1 ± 3.0 89.0 ± 2.5 70.0 ± 0.8
Heart Weight/Body Weight 
(ratio)
*
Tibia length/Body Weight 
(ratio)
*p<0.05 vs control
AG 490 Water AG 490 Water
*
 
Control mouse hearts that were, given plain drinking water were subjected to a 
permanent ligation had an EF of 48±3% and FS of 20±3% (see Figures 59 and 60). Pre-
treatment with AG490 had no effect (ns vs. control). Melatonin treatment on its own 
improved EF from 48±3% to 80±1% (p<0.001). Treatment with melatonin also improved 
FS from 20±3% to 40± 3% compared to controls.However, addition of AG490, with 
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melatonin did not abolish the protective effect of melatonin and presented with an EF of 
75± 2 %( ns versus melatonin group) and FS of 38.2±2.8%.  
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Figure 58: EF (ejection fraction) was assessed by echocardiography after 28 days ligation in the presence 
or absence of AG490 in wild-types mice receiving  either water or melatonin treatment.. 
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Figure 59: FS (fractional shortening) was assessed by echocardiography after 28 days ligation in the 
presence or absence of AG490 performed in wild-types mice receiving  either water or melatonin 
treatment. 
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5. Discussion 
The previous chapters have shown that melatonin administered acutely and chronically 
(over a 14-day period) protects the heart in a model of I/R injury. The present chapter 
extends our findings to a model of IHF. We have shown that the chronic moderate 
consumption of melatonin given daily at physiological concentrations can ameliorate the 
detrimental effect of HF using STAT3KO and TNFKO mice, our data suggest that this 
cardioprotective effect of melatonin is independent of the SAFE pathway 
5.1. Validation of IHF model 
The mice underwent a permanent ligation of the left descending coronary artery, 2 mm 
below the auricle, and were maintained for 28 days. Although this model is commonly 
used and described in the literature, it is questionable whether 28 days is sufficient for 
the progression of HF (Gao et al., 2000). HF is a complex syndrome that develops over 
time: the heart function becomes impaired and fails to pump. In humans, a heart beating 
with an EF of 50% is fully functional, thus the EF must drop below 50% for impairment 
(Chu et al., 2009). In IHF the infarct progresses and leads to myocyte damage, reduced 
contractility and eventually the dysfunction of the left ventricle (Chu et al., 2009). The 
size and location of the infarct will influence the progression of HF. Therefore, in the 
current study it would be imperative that infarct size be measured, to give a better 
indication of the development of IHF. Furthermore, in the current experiments 
conducted in the STAT3 KO, TNF KO and their wild-type littermates and wild-type mice 
with the C5BL6 background, all presented with a mean ejection fraction of ±50% post 
infarction but with a significant drop in FS to ±20%. Therefore the mouse hearts are 
functioning at a capacity of 50% and would not be considered failing in a human setting 
(Fox et al., 2001). In a mouse model of IHF, the EF decreases to ±30% before it is 
considered failing. However, in the mouse, the extent of typical cavity obliteration is far 
greater than in man, so that the normal EF is near 90%. It is therefore much more 
common to use FS% as the basic measure of ventricular function and is the most 
common method for the analysis of left ventricular function in mice (as reviewed by 
Rottman et al.,  2007; Chu et al., 2002). Furthermore, even after a permanent ligation a 
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mouse heart continues to beat at 400-600 beats/minute as compared to a human heart 
60-90 beats/minute. The elevated heart rate in mice highlights differences in calcium 
handling and muscle contraction (Barry et al., 1999). Thus distinct variations persist in a 
mouse model when compared to clinical setting (Chu et al., 2002). Again, this raises the 
question whether the model used in our study is sufficient to mimic HF or merely an 
illustration of the progression toward HF. In the literature, most mouse studies utilise 
aortic banding to induce an abnormal pressure overload, these mice develop HF within 
weeks (Barry et al., 1999). Therefore, for future studies a different model of HF could be 
utilised to determine whether the outcome remains the same. Another alternative would 
be to keep mice for an extended time frame to fully declare the progression of HF. 
5.2. Melatonin protects against IHF   
In our previous study, in Chapter 2, the daily and moderate consumption of melatonin at 
physiological concentrations protected the heart against I/R injury in an isolated mouse 
model as well as in vivo. There have been many studies that demonstrate the 
cardioprotective effects of melatonin, at high concentrations (Lochner et al., 2006, Tan 
et al., 1993, Tan et al.,1998) but studies explore the cardioprotective role of melatonin in 
IHF. Interestingly, there are clinical trials that have suggested a relationship between 
melatonin and coronary heart disease (Brugger et al., 1995). Brugger et al., found 
reduced melatonin levels in the plasma, at night (02:00h) in patients with coronary 
artery disease (Brugger et al., 1995). It would be of future importance to measure the 
level of melatonin in IHF patients. 
In this chapter the long-term consumption of melatonin reduced the HW/BW ratio in 
wild-type mice when compared to the plain drinking water controls. The heart weight to 
body ratio were first measured in 1884 to draw correlations between increased heart 
mass and hypertrophy (Bergman et al., 1884, Chu et al.,2002). Furthermore, melatonin 
administration reduced the HW/BW ratio in TNFKO, STA3KO and their respective wild-
type littermates therefore these hearts had not developed compensatory hypertrophy 
and are fairly functional.  
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The hemodynamic parameters were also measured in all mice. Prior to the ligation 
there was no difference between the plain drinking water controls and the melatonin 
treated groups. However, after 28 days the controls given the drinking water had a 
reduced ejection fraction and fractional shortening of 50%. The wild-type mice given 
melatonin treatment also had a pronounced improvement in ejection fraction and 
fractional shortening. Interestingly, this protective effect of melatonin persisted in 
STAT3KO and TNFKO mice. Melatonin protected even in the presence of AG490 the 
STAT3 inhibitor.   
5.3. Melatonin confers cardioprotection via STAT3 
Low concentrations of melatonin administered daily protects in wild-type mice in the 
presence or absence of AG490, the JAK/STAT3 antagonist. B th the EF and FS were 
improved in melatonin-treated groups compared to the water controls that received no 
treatment. This may imply that the protective effect of melatonin is independent of 
STAT3. However, AG490 is a non-selective antagonist for JAK2 and not STAT3, thus 
further investigations are required to verify these results (Schaefer et al., 1995). Another 
alternative would be to administer a more specific inhibitor such as Stattic, a direct 
STAT3 antagonist. 
In the wild-type littermates melatonin preserves EF and FS compared to the controls 
that received plain drinking water. Surprisingly, this protective effect persisted in 
cardiomyocyte specific STAT3 KO mice, contrary to the studies performed in vitro 
(Lamont et al., 2010). A possible reason for this is that the in vitro studies were 
performed acutely; a once-off bolus dose of melatonin was administered. In the current 
model the same dose of melatonin was administered chronically over a 28-day period. 
The literature has demonstrated that excess levels of STAT3 may induce apoptosis, 
hypertrophy and HF (Oshimo et al., 2005, Lecour & James. 2011). The JAK/STAT3 
pathway is an intricate pathway that requires cytokine activation (Rodig et al., 1998). In 
this model the inflammatory mediators are elevated, which in turn leads to the chronic or 
excessive stimulation of STAT3 which can promote the onset of HF (Sood et al., 2006). 
Alternatively, the chronic activation of the JAK/STAT3 pathway can lead to the up- 
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regulation of NFkB which in turn promotes the activation of metalloproteinase release 
and apoptosis (Gross et al., 2006 and Kunisada et al., 2003). Thus in this model of IHF, 
it is fitting that melatonin protects in the STAT3 KO mice, because there is no excessive 
accumulation STAT3, therefore confirming the initial findings that demonstrated the 
protective effect of melatonin in the presence or absence of AG490. 
5.4. Melatonin protects in TNF KO mice  
TNFα is one of the cytokines activated during ischemia-reperfusion injury (Lecour et al., 
2005, Lacerda et al., 2009, Deucher et al., 2007) and contributes to cardiac dysfunction 
and apoptosis (Dorge et al., 2002). However, the release of TNFα is both adaptive and 
maladaptive: it evokes a healing response as well as attacking the invaders (Lecour & 
James 2011). Nonetheless, the different roles of TNFα are both concentration- and 
receptor- dependent.  It has been shown that high concentrations of TNFα are 
detrimental, whereas lower concentrations of TNFα are beneficial (Lecour et al., 2005). 
Furthermore, TNF receptor 1 is believed to activate a death signal because it stimulates 
the release of caspase 3 and 8 which in turn promote the release of cytochrome C, 
which are proapoptotic factors. On the contrary, TNF receptor 2 activates antiapoptotic 
factors including the JAK/STAT pathway and confers cardioprotection.  
A remarkable feature about IHF is that the syndrome is accompanied with both a 
systemic and local inflammatory response and contributes to the progressive 
deterioration of the heart (Chen et al., 2008). In the Vesnarinone (VEST) trial a strong 
correlation between high levels of TNF and functional stages of HF were identified, with 
poorer prognosis for those with high TNF levels (Deswal, 2001). This may be due to a 
negative ionotrophic action and disturbance of the β adrenoreceptor sensitivity caused 
by excessive TNF release (Deswal et al., 2001). In patients with myocardial infarction, 
TNF levels are also increased (Cesari et al., 2003). Interestingly, in the current study, 
melatonin protected in the wild-type mice when compared to those that drank plain 
drinking water. Surprisingly, melatonin induced cardioprotection persisted in TNF KO 
mice with improved EF and FS. A possible reason for this is that melatonin also exerts 
an effect on the adrenoreceptors especially via its receptor 3 as demonstrated in the 
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chronic studies performed in the previous chapter. Thus in the absence of TNFα 
melatonin restores the optimal function of the adrenoreceptors and confers 
cardioprotection (Deswal et al., 2001). However, in an isolated heart model an acute 
dose of melatonin was administered prior to I/R and the protective effect of melatonin 
was lost in TNF-deficient mice but this was not a long term model. Thus, in IHF there is 
a chronic release of cytokines with increased hemodynamic overload (Kleinbongard et 
al., 2010, Dorge et al., 2002). The invasion of cytokines into the myocardium are 
prevented in TNF KO mice therefore, the cytokine levels are not excessive as normally 
displayed. In light of this it is understandable that melatonin successfully protects in TNF 
KO mice. Therefore, the effects of IHF, hypertrophy, inflammation, apoptosis and overall 
cell death are reduced without the binding of TNFα to its receptor 1 (Chrysohou et al., 
2009). 
5.5. Melatonin protects independently of the SAFE pathway 
The two integral parts of the survivor activating factor enhancement (SAFE) pathway 
are TNFα and STAT3. This pathway has been shown to be cardioprotective in I/R injury 
(Lacerda et al., 2009, Lecour S. 2009). However, in a model of IHF both STAT3 and 
TNF are upregulated; the chronic stimulation of these compounds can lead to 
hypertrophy (Kunidisada et al., 2001). In experimental IHF, TNFR1 and TNFR2 have 
opposing effects on heart remodelling and hypertrophy (Schulz et al., 2009). Therefore, 
drugs used for the treatment of HF should be specific to enhance the activation TNFR2. 
Furthermore there is evidence that the chronic stimulation of gp130-mediated activation 
of JAK/STAT3 promotes cardiac inflammation, adverse remodelling and HF in mice with 
MI (Kleiner et al., 2010). Our data show that, melatonin protects independently of the 
SAFE pathway in a model of IHF as chronic activation of the SAFE pathway is likely to 
worsen HF. Somehow melatonin has been able to adapt to this physiological condition 
and “switch off” the SAFE pathway to confer cardioprotection. The mechanism involved 
in this regulation still remain to be delineated but may involve the Toll like receptor 
activation known to regulate TNFα. The mechanism by which melatonin protects against 
IHF still remain to be delineated. Melatonin is known to activate Akt (Genade et al., 
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2008) but, again, chronic stimulation of Akt can lead hypertension and therefore worsen 
IHF (Buss et al., 2012). Further studies will be required to determine the exact 
mechanism in melatonin induced cardioprotection against IHF and it is likely that 
melatonin protects via its direct anti-oxidant effect (Mahal et al., 1999). 
In conclusion, our data demonstrate that melatonin is a powerful, cheap and safe drug 
to consider in patients with IHF. 
Melatonin
Protects in ischemic 
heart failure
NOT via the SAFE 
pathway?

 
Figure 60: Melatonin confers cardioprotection in a model of ischemic HF but not via the SAFE pathway. 
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E. Final Discussion    Closing Remarks 
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Several epidemiological studies have shown that the regular moderate consumption 
of red wine reduces the effects of cardiovascular disease, as demonstrated in the 
French population (St Leger et al., 1979, de Lorgeril et al., 2002). Our study has 
demonstrated that the chronic and moderate consumption of red wine, equivalent to 
2-3 glasses of red wine/day, can protect against ischemia-reperfusion injury both in 
an isolated heart model and in vivo. Many postulated that the presence of resveratrol 
predominantly present in red wine, may explain the cardioprotective effect of red 
wine. However, high concentrations of resveratrol have been given experimentally 
and not the actual concentration as that found in red wine (Bauer et al., 2002 and 
Pellegatta et al., 2003).  
In Chapter 1, the acute administration of resveratrol (10µM) protected against IR 
injury in the isolated heart model. In contrast, the chronic and regular administration 
of resveratrol, given at the concentration to that found in red wine did not protect 
against IR injury. Hence, our data therefore suggest that other components may 
contribute to the beneficial effect of red wine. In 2008, Guerrero and collaborators 
found that melatonin was present in red wine (Guerrero et al., 2008). One hour after 
the consumption of 100mℓ of red wine the melatonin levels in the blood plasma were 
increased (Guerrero et al., 2008). Our findings demonstrate that melatonin, given at 
a similar concentration to 2-3 glasses of red wine/day, protected against I/R injury to 
a similar extent as red wine given on its own. To investigate the role of melatonin in 
red wine induced cardioprotection, luzindole (melatonin receptor 1 & 2 inhibitor) and 
prazosin (melatonin receptor 3 inhibitor) were used. The literature has shown that 
melatonin given at higher concentrations (40µg/ℓ) exert its protective effects via the 
activation of melatonin receptor 1 and 2 (Genade et al., 2008). However, the 
inhibition with luzindole in our study reduced the infarct sparing ability of melatonin 
but failed to abolish the protective effect of red wine. Prazosin abolished the 
protective effect of melatonin and partially attenuated the cardioprotective effect of 
red wine. Thus melatonin present in red wine is one of the key cardioprotective 
components in the red wine that confer its effect via the activation of MT3, this was a 
major milestone in our study. However, melatonin is not the only compound present 
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in red wine that confers a cardioprotective effect. Red wine contains 1000 different 
compounds, including alcohol, resveratrol and melatonin which may have different 
effects when supplemented together. It is therefore possible that a synergestic 
action, between several compounds contribute to the beneficial effects of red wine. 
Previous studies show that melatonin at high concentrations protects via the 
activation of the Akt/Erk pathway (Genade et al., 2008). Furthermore, melatonin 
inhibits the opening of the mitochondrial permeability pore (Petrosillo et al., 2009) a 
downstream target of the SAFE pathway. Our study demonstrated for the first time 
that red wine induced cardioprotection was modulated by melatonin and that this 
protective effect was mediated via the activation of the powerful prosurvival SAFE 
pathway. The SAFE pathway involves the activation of the innate immune system 
(TNFα) and STAT3. We have shown that melatonin, at the concentration found in 
red wine which is similar to physiological concentrations, protects against I/R injury. 
However, whether this protective effect could be extended to a model of IHF, with 
long term melatonin administration, required investigation.  
In chapter 3, we explored the cardioprotective effect of melatonin in IHF. 
Interestingly, in our study the long term use of melatonin in a model of IHF improved 
ejection fraction and fractional shortening when compared to the mice that received 
plain drinking water. However, the protective effect of melatonin persisted in both 
TNFα and STAT3 KO mice, contrary to previous findings in chapter 1. Thus the long 
term administration of melatonin in IHF protects independently of the SAFE pathway. 
A possible reason for this is, excess release of TNFα is mediated via TNF receptor 1 
in HF (Deswal et al., 2001). Also it has been suggested that excessive STAT3 
release promotes a death signal in the heart (Kunisade et al., 2000). In summary, we 
demonstrate the significance of melatonin as a vital component present in red wine 
that contributes to its beneficial effect. Furthermore, the protective effect of both red 
wine and melatonin are mediated via the activation of the SAFE pathway, in a model 
of myocardial infarction. In a long term model, the bioavailability of the compounds in 
the wine and rate of absorption, in the gut may have an effect on the mechanism of 
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protection. Thus, this may give a possible explanation why the long-term 
administration of melatonin protectsindependently of the SAFE pathway in IHF. 
 
The main novel findings: 
1) Regular and moderate consumption of red wine, equivalent to 2-3 glasses  
 of red wine/day confers cardioprotection against ischemia-reperfusion injury. 
 
2) Melatonin, at the low concentration as found in red wine, contributes to  
red wine-induced cardioprotection against I/R injury. 
3) Red wine and melatonin-induced cardioprotection against I/R injury 
are mediated via the activation SAFE pathway (TNFα and STAT3 activation). 
 
4) Melatonin, at the concentration found in red wine, protects in a model of IHF. 
 
5) Melatonin induced cardioprotection against IHF is independent of the SAFE 
 pathway activation  
 
 
Future directions 
Melatonin is a cheap compound that is easily accessible, over the counter and may 
be used as an adjunctive therapy for patients with ischemic HF. It would be of 
interest to measure melatonin in the blood samples of HF patients to confirm 
reduced melatonin secretion. To prove the cardioprotective effect of melatonin in red 
wine induced cardioprotection we have used non specific melatonin inhibitors. To 
further explore our hypothesis melatonin knockout mice would be ideal. However, 
MT3 knockout mice are not available because this receptor has not been fully 
characterized. Therefore, in collaboration with University of Stellenbosch we aim to 
use synthetic wine and compare the cardioprotective effects with or without 
melatonin.  
Since both red wine and melatonin protect via the activation of the SAFE pathway it 
is imperative to explore what lies upstream and downstream of the SAFE pathway. 
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Preliminary studies performed have shown that the infarct sparing ability of 
melatonin is abolished in the presence of a toll like receptor 4 inhibitor which may act 
as a potential upstream activator of the SAFE pathway is toll like receptor 4. 
Furthermore, we have also started to explore the idea of the mitochondria as the end 
target for melatonin induced cardioprotection, these data are incomplete and are not 
shown.  
In conclusion, melatonin is a pleiotrophic compound that can exert a variety of 
protective effects via different mechanisms. Thus, the use of such a compound in 
developing countries where both IHD and HF are on the incline may be of benefit to 
alleviate the burden of CVD. Furthermore, melatonin is cheap, safe and easily 
accessible to various socioeconomic groups. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 127  
 
 
 
 
 
 
 
 
 
 
 
 
F. Publications and conference outputs 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Page | 128  
 
Publication list 
 Lamont KT, Blackhurst D, Marais D, and Lecour S. Lowering the degree of 
alcohol in red wine does not alter its cardioprotective effect. SAMJ. 2012, 102: 6. 
 Lamont KT, Sarin S, Lacerda L, Opie LH, Lecour S.Is red wine a SAFE sip away 
from cardioprotection? Mechanisms involved in resveratrol and melatonin-induced 
cardioprotection. J of Pineal Res. 2011, 50:374-380. 
 Lecour S and Lamont KT.  Natural polyphenols and cardioprotection. Mini 
reviews in Medicinal Biochemistry. 2011, 14: 1191-9. 
  Opie LH, Lamont KT and Lecour S. Wine and heart health: learning from the 
French Paradox. South African Heart Journal 2011, 8: 172-77.  
 Kelly RF, Lamont KT, Somers S, Hacking D, Thomas P, Opie LH, Lecour S 
Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol. 
2010 Nov; 105(6): 763-70. 
 
Conference outputs 
 Lamont KT, Opie LH, Lecour S: Regular moderate consumption of red wine 
confers cardioprotection via melatonin and STAT3 activation, European heart Society, 
Paris 2011 (Poster). 
 Lamont KT, Opie LH, Lecour S: Sleep your way to cardioprotection: Melatonin is 
responsible for red wine induced protection, International Society of Heart Research, 
Japan. 2010 (Poster ). JMCC 48:S1-S185. 
 Lamont KT, Opie LH, Lecour S. Melatonin activates the transcription factor 
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